[
  {
    "id": "ecd-1",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 40,
    "sampleVolumeMin": 2,
    "sampleTubeType": "Guardant cfDNA BCT",
    "sampleTubeCount": 4,
    "sampleCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/shield-p230009 | https://shieldcancerscreen.com/",
    "name": "Shield",
    "vendor": "Guardant Health",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA screening (plasma)",
    "method": "NGS detecting cfDNA methylation patterns + fragmentomics + somatic mutations (~1Mb genome coverage)",
    "cancerTypes": [
      "Colorectal cancer (colon and rectal)"
    ],
    "targetPopulation": "Average-risk adults 45-84 years without prior CRC; adenomas; IBD; or hereditary CRC syndromes",
    "indicationGroup": "CRC",
    "sensitivity": 83.1,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "advancedAdenomaSensitivity": 13.2,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "advancedAdenomaSensitivityNotes": "Limited sensitivity for precancerous advanced adenomas (13.2%); blood-based tests generally less effective at detecting polyps than stool-based tests.",
    "stageISensitivity": 54.5,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "stageIISensitivity": 100,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "stageIIISensitivity": 100,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "stageIVSensitivity": 100,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009C.pdf",
    "specificity": 89.6,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "ppv": 3.1,
    "ppvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf | https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "ppvDefinition": "PPV 3.10% for colorectal cancer (CRC) at age-adjusted 0.42% prevalence in ECLIPSE average-risk screening population (FDA SSED Table 16)",
    "npv": 99.92,
    "npvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf | https://pubmed.ncbi.nlm.nih.gov/38477985/",
    "npvDefinition": "NPV 99.92% for absence of CRC at age-adjusted prevalence in ECLIPSE average-risk screening population (FDA SSED Table 16)",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/38477985/ | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230009B.pdf",
    "performanceNotes": "In ECLIPSE cfDNA blood test showed 83% sensitivity for CRC with 90% specificity. Stage I sensitivity 55-65%; limited detection of advanced adenomas (13.2%).",
    "leadTimeNotes": "No formal lead-time vs colonoscopy; positioned as guideline-accepted primary screening option every 3 years in average-risk adults",
    "fdaStatus": "FDA-approved PMA (P230009) July 26 2024 - First blood test for primary CRC screening",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage per NCD 210.3; commercial coverage expanding",
    "commercialPayers": [],
    "commercialPayersCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Healths-Shield-Blood-Test-Now-Covered-for-VA-Community-Care-Beneficiaries/default.aspx",
    "commercialPayersNotes": "No commercial payer coverage yet. Government programs: VA Community Care Network covers Shield with no copay for average-risk individuals 45+; TRICARE also covers. Commercial insurance coverage pending USPSTF guideline inclusion and ACS recommendations. Once included in guidelines, expected to be covered under ACA preventive services.",
    "availableRegions": [
      "US"
    ],
    "clinicalAvailability": "Commercially available in US since August 2024",
    "tat": "~14 days",
    "tatCitations": "https://www.stocktitan.net/news/GH/shield-crc-blood-test-demonstrates-adherence-of-95-in-new-study-of-tchgb4rvn3op.html",
    "tatNotes": "Median test turnaround time of 15 days from blood sample receipt to results report in real-world study of 20,000 patients.",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes",
    "sampleVolume": "4 tubes (minimum 2 mL plasma)",
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "0537U",
    "codeType": "PLA",
    "medicareRate": 1495,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "listPrice": 895,
    "listPriceCitations": "https://www.cnn.com/2024/07/29/health/fda-colorectal-cancer-screening-blood-test | https://www.aafp.org/pubs/afp/issues/2023/0600/diagnostic-tests-guardant-health-shield-colon-cancer.html",
    "screeningInterval": "Every 3 years",
    "clinicalTrials": "NCT04136002 ECLIPSE CRC screening study (22877); NCT05716477 OSU Guardant Shield CRC Screening Project (300)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04136002 | https://clinicaltrials.gov/study/NCT05716477",
    "totalParticipants": 23177,
    "totalParticipantsCitations": "https://clinicaltrials.gov/study/NCT04136002 | https://clinicaltrials.gov/study/NCT05716477",
    "numPublications": 5,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colorectal Cancer Screening V.1.2025 (June 2025)",
    "nccnGuidelinesNotes": "Added to NCCN CRC Screening Guidelines in June 2025 as an acceptable screening option for average-risk adults with 3-year screening interval recommendation. First blood-based test included in NCCN CRC screening guidelines."
  },
  {
    "id": "ecd-2",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "sampleCitations": "https://www.galleri.com/patient/faqs | https://grail.com/wp-content/uploads/2022/05/GRAIL-OUS-4-tube-Standard-Kit-Specimen-Collection-Instructions.pdf",
    "name": "Galleri",
    "vendor": "GRAIL",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Tumor-naïve cfDNA methylation profiling with targeted NGS + machine-learning classifier; predicts cancer signal and tissue of origin (CSO)",
    "cancerTypes": [
      "50+ cancer types including colorectal, lung, pancreas, ovary, liver, head & neck, lymphoma, esophagus, stomach, bile duct, etc."
    ],
    "targetPopulation": "Asymptomatic adults ≥50 years as adjunct to standard single-cancer screening",
    "indicationGroup": "MCED",
    "sensitivity": 51.5,
    "sensitivityCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/",
    "stageISensitivity": 16.8,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "stageIISensitivity": 40.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "stageIIISensitivity": 77,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "stageIVSensitivity": 90.1,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34176681/ | https://www.annalsofoncology.org/article/s0923-7534(21)02046-9/fulltext",
    "specificity": 99.5,
    "specificityCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/",
    "ppv": 61.6,
    "ppvCitations": "https://www.galleri.com/hcp/galleri-test-performance",
    "ppvDefinition": "PPV for any cancer among participants with Cancer Signal Detected",
    "npv": 99.1,
    "npvCitations": "https://www.galleri.com/hcp/galleri-test-performance",
    "npvDefinition": "NPV for remaining cancer-free after No Cancer Signal Detected (12-month follow-up)",
    "tumorOriginAccuracy": 93,
    "tumorOriginAccuracyNotes": "Cancer Signal Origin (CSO) prediction accuracy: 93% top-1 prediction, 97% top-2 predictions in CCGA validation studies",
    "performanceCitations": "https://www.galleri.com/hcp/galleri-test-performance | https://pmc.ncbi.nlm.nih.gov/articles/PMC11024170/ | https://grail.com/press-releases/final-results-from-pathfinder-study-of-grails-multi-cancer-early-detection-blood-test-published-in-the-lancet/ | PATHFINDER-2 ESMO 2025",
    "performanceNotes": "Overall cancer signal sensitivity ~51.5% with stage-specific sensitivity rising from ~17% at stage I to ~90% at stage IV; specificity ~99.5-99.6%. PATHFINDER-2 (Oct 2025, n=23,000+): Galleri detected cancers ~7× more often than USPSTF A/B standard screening; ~62% of positive tests (Cancer Signal Detected) confirmed as cancer in follow-up, substantially higher PPV than earlier versions.",
    "leadTimeNotes": "PATHFINDER and PATHFINDER 2 show ~7-fold increase in cancers detected when added to USPSTF A/B screening; median diagnostic resolution ~1.5 months",
    "fdaStatus": "LDT performed in CLIA-certified CAP-accredited lab; not FDA-approved; Breakthrough Device designation; PMA submission expected H1 2026",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Generally self-pay; most insurers and Medicare do not cover MCED as of 2025; TRICARE covers for ≥50 with elevated risk. REACH study: Medicare covers Galleri test and related workup for enrolled REACH participants (coverage of research, not general NCD).",
    "reimbursementCitations": "https://grail.com/press-releases/grail-announces-first-participant-enrolled-in-reach-study-evaluating-clinical-impact-of-galleri-multi-cancer-early-detection-mced-test-in-the-medicare-population/",
    "commercialPayers": [
      "Curative Insurance",
      "Fountain Health",
      "Alignment Health Plan"
    ],
    "commercialPayersCitations": "https://grail.com/press-releases/curative-insurance-company-adds-grails-galleri-test-to-member-benefits-for-multi-cancer-early-detection/",
    "commercialPayersNotes": "Limited commercial coverage. Curative Insurance and Fountain Health offer $0 copay coverage. Alignment Health Plan (Medicare Advantage) covers in select CA/NC plans. Government programs: TRICARE covers with prior authorization for eligible beneficiaries ≥50. Most major commercial insurers consider investigational.",
    "availableRegions": [
      "US",
      "UK"
    ],
    "clinicalAvailability": "Commercially available in US and some international markets as CLIA test since June 2021",
    "tat": "10-14 business days (up to 4 weeks during high volume)",
    "tatCitations": "https://www.galleri.com/lab-info | https://www.galleri.com/patient/faqs",
    "tatNotes": "Typically about 2 weeks from sample receipt; occasionally up to 4 weeks during high volume periods.",
    "sampleType": "Whole blood in Streck cfDNA BCT tubes",
    "sampleVolume": "2 tubes",
    "sampleStability": "7 days at ambient temperature (1-40°C); do not refrigerate/freeze",
    "cptCode": "Proprietary",
    "listPrice": 949,
    "listPriceCitations": "https://www.galleri.com/hcp/faqs",
    "screeningInterval": "Annual recommended",
    "clinicalTrials": "NCT05611632 NHS-Galleri randomized screening trial (~140000); NCT05155605 PATHFINDER 2 safety/performance study (~23000+, results Oct 2025); NCT03934866 SUMMIT high-risk lung cohort (13035); REACH study (Medicare coverage of research)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05611632 | https://clinicaltrials.gov/study/NCT05155605 | https://clinicaltrials.gov/study/NCT03934866 | https://grail.com/press-releases/grail-pathfinder-2-results-show-galleri-multi-cancer-early-detection-blood-test-increased-cancer-detection-more-than-seven-fold-when-added-to-uspstf-a-and-b-recommended-screenings/",
    "totalParticipants": 188535,
    "totalParticipantsCitations": "https://clinicaltrials.gov/study/NCT05611632 | https://clinicaltrials.gov/study/NCT05155605 | https://clinicaltrials.gov/study/NCT03934866",
    "numPublications": 20,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-3",
    "sampleCategory": "Stool",
    "name": "Cologuard Plus",
    "vendor": "Exact Sciences",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool-based multitarget DNA test",
    "method": "Multitarget stool DNA assay with 5 novel methylation markers + hemoglobin immunoassay; streamlined from original 11 markers",
    "cancerTypes": [
      "Colorectal cancer; Advanced precancerous lesions (APL); High-grade dysplasia"
    ],
    "targetPopulation": "Average-risk adults 45-75 years for CRC screening at home",
    "indicationGroup": "CRC",
    "sensitivity": 93.9,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",
    "advancedAdenomaSensitivity": 43.4,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "advancedAdenomaSensitivityNotes": "43% sensitivity for advanced precancerous lesions (APL) including advanced adenomas and sessile serrated lesions ≥1cm; significantly outperforms FIT (23% for APL).",
    "stageISensitivity": 87,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIISensitivity": 94,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIIISensitivity": 97,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "stageIVSensitivity": 100,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "specificity": 91,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992 | https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2024/FDA-Approves-Exact-Sciences-Cologuard-Plus-Test-Setting-a-New-Benchmark-in-Non-Invasive-Colorectal-Cancer-Screening/default.aspx",
    "ppv": 3.2,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in BLUE-C average-risk screening population",
    "npv": 99.98,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38477992/",
    "npvDefinition": "NPV for absence of CRC in BLUE-C average-risk screening population",
    "performanceCitations": "BLUE-C pivotal trial NEJM 2024 (n=20000+); DeeP-C studies; FDA PMA labeling 2024",
    "performanceNotes": "Pivotal BLUE-C trial: 94% sensitivity for CRC and 43% for APL; significantly outperforms FIT (94% vs 67% for CRC; 43% vs 23% for APL). FDA-approved label (Oct 2024) and March 2025 launch materials emphasize **95% CRC sensitivity at 94% specificity** in the U.S. screening population, with ~40% fewer false positives vs original Cologuard.",
    "leadTimeNotes": "Non-invasive alternative to colonoscopy; 30% lower false positive rate vs original Cologuard; significantly improved adherence vs colonoscopy",
    "fdaStatus": "FDA-approved PMA October 4 2024",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage; $0 out-of-pocket for eligible; broad commercial payer coverage",
    "commercialPayers": [
      "Humana"
    ],
    "commercialPayersCitations": "https://www.cologuard.com/insurance",
    "commercialPayersNotes": "Cologuard Plus confirmed coverage: Medicare Part B and Humana Medicare Advantage. Government programs: TRICARE expected based on legacy Cologuard coverage. Other major commercial payers (UnitedHealthcare, Aetna, Cigna, Anthem BCBS) anticipated to extend legacy Cologuard coverage to Plus but should be validated per plan.",
    "clinicalAvailability": "Commercially launched late March 2025 via ExactNexus (350+ health systems)",
    "tat": "3-5 days from receipt",
    "sampleType": "At-home stool collection with enhanced preservatives",
    "sampleVolume": "Stool sample",
    "sampleStability": "Extended return window vs original",
    "cptCode": "0464U",
    "listPrice": 790,
    "screeningInterval": "Every 3 years",
    "clinicalTrials": "NCT04144738 BLUE-C pivotal Cologuard Plus CRC screening trial (26758)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04144738",
    "totalParticipants": 26758,
    "numPublications": 2,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colorectal Cancer Screening Guidelines",
    "nccnGuidelinesNotes": "Multitarget stool DNA (mt-sDNA) testing is standard of care inclusion in NCCN CRC Screening guidelines. Cologuard Plus is the FDA-approved mt-sDNA test from Exact Sciences.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1429"
  },
  {
    "id": "ecd-4",
    "sampleCategory": "Stool",
    "name": "ColoSense",
    "vendor": "Geneoscopy",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool-based multitarget RNA test",
    "method": "8 stool-derived eukaryotic RNA (seRNA) transcripts via ddPCR + FIT - first FDA-approved RNA-based cancer screening test",
    "cancerTypes": [
      "Colorectal cancer; Advanced adenomas; Sessile serrated lesions"
    ],
    "targetPopulation": "Average-risk adults 45+ years for CRC screening",
    "indicationGroup": "CRC",
    "sensitivity": 93,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",
    "stageISensitivity": 100,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "stageIISensitivity": 71.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "stageIIISensitivity": 100,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "specificity": 88,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717 | https://www.accessdata.fda.gov/cdrh_docs/pdf23/P230001B.pdf",
    "ppv": 1.9,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "ppvDefinition": "PPV for colorectal cancer (CRC) in PMA primary effectiveness cohort",
    "npv": 94.4,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/37930717/",
    "npvDefinition": "NPV for no advanced colorectal neoplasia (NAPL or negative colonoscopy)",
    "performanceCitations": "CRC-PREVENT JAMA 2023 (n=14263)",
    "performanceNotes": "CRC sensitivity 93-94% with 100% Stage I detection; advanced adenoma 45-46%; specificity 88%; outperforms FIT (94% vs 78% CRC; 46% vs 29% AA).",
    "leadTimeNotes": "Non-invasive RNA-based alternative; 100% Stage I sensitivity notable",
    "fdaStatus": "FDA-approved PMA May 3 2024; Breakthrough Device Designation January 2020",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Medicare coverage pending - NCD reconsideration requested; NCCN Guidelines included",
    "commercialPayers": [],
    "commercialPayersCitations": "",
    "commercialPayersNotes": "Emerging commercial and Medicaid coverage; no stable payer list yet. Medicare coverage pending NCD reconsideration.",
    "clinicalAvailability": "Launched via Labcorp partnership late 2024/early 2025",
    "tat": "Not publicly specified",
    "sampleType": "At-home stool collection (simplified kit FDA-approved 2025)",
    "sampleVolume": "Stool sample",
    "sampleStability": "Not specified",
    "cptCode": "0421U",
    "listPrice": 508.87,
    "screeningInterval": "Every 3 years (USPSTF)",
    "clinicalTrials": "NCT04739722 CRC-PREVENT pivotal ColoSense stool RNA CRC screening trial (14263)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04739722",
    "totalParticipants": 8920,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-6",
    "name": "Freenome CRC Blood Test",
    "vendor": "Freenome",
    "sampleCategory": "Blood/Plasma",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA multiomics (plasma)",
    "method": "AI/ML analyzing genomic + epigenomic (single-base methylation) + proteomic biomarkers",
    "cancerTypes": [
      "Colorectal cancer; Advanced adenomas"
    ],
    "targetPopulation": "Average-risk adults for CRC screening",
    "indicationGroup": "CRC",
    "sensitivity": 79.2,
    "sensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",
    "stageISensitivity": 57.1,
    "stageISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIISensitivity": 100,
    "stageIISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIIISensitivity": 82.4,
    "stageIIISensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "stageIVSensitivity": 100,
    "stageIVSensitivityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer/",
    "specificity": 91.5,
    "specificityCitations": "https://www.freenome.com/newsroom/freenome-announces-topline-results-for-preempt-crc-to-validate-the-first-version-of-its-blood-based-test-for-the-early-detection-of-colorectal-cancer | https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.18",
    "ppv": 2.7,
    "ppvCitations": "PREEMPT CRC JAMA 2025; Freenome Newsroom",
    "ppvNotes": "PPV ~2.7% in average-risk screening population. Low PPV typical for screening tests where disease prevalence is low (~0.5-1%).",
    "ppvDefinition": "PPV for CRC in PREEMPT CRC average-risk screening population",
    "npv": 99.8,
    "npvCitations": "PREEMPT CRC JAMA 2025; Freenome Newsroom",
    "npvNotes": "NPV 99.8% - high NPV indicates negative result reliably rules out CRC",
    "npvDefinition": "NPV for CRC in PREEMPT CRC average-risk screening population",
    "performanceCitations": "PREEMPT CRC JAMA June 2025 (n=48995 enrolled; 27010 analyzed)",
    "performanceNotes": "79.2% CRC sensitivity with 57.1% Stage I; 12.5% advanced adenoma (29% for high-grade dysplasia); 91.5% specificity.",
    "leadTimeNotes": "Largest blood-based CRC screening study (PREEMPT CRC n=48995); multiomics approach combines multiple biomarker classes",
    "fdaStatus": "PMA application submitted (final module August 2025); Exact Sciences exclusive US licensing agreement announced August 2025",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not yet established",
    "clinicalAvailability": "Not yet commercially available - pending FDA approval",
    "tat": "14 days",
    "tatNotes": "Expected TAT ~14 days based on similar blood-based CRC tests; final TAT to be confirmed at launch",
    "listPrice": 895,
    "listPriceNotes": "Expected price ~$895-$1,500 based on Exact Sciences licensing agreement and comparable tests (Shield $895)",
    "sampleType": "Blood",
    "sampleVolume": "Not specified",
    "sampleStability": "Not specified",
    "cptCode": "UNKNOWN",
    "screeningInterval": "Expected every 3 years",
    "clinicalTrials": "NCT04369053 PREEMPT CRC registrational Freenome blood-based CRC screening study (48995 enrolled; 27010 analyzed)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT04369053",
    "totalParticipants": 48995,
    "numPublications": 2,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-7",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 1,
    "sampleCitations": "https://delfidiagnostics.com/firstlook-lung/",
    "name": "FirstLook Lung",
    "vendor": "DELFI Diagnostics",
    "testScope": "Single-cancer (Lung)",
    "approach": "Blood-based cfDNA fragmentomics",
    "method": "Low-pass whole genome sequencing analyzing cfDNA fragment length patterns + ML classifier - detects chaotic DNA packaging from cancer cells",
    "cancerTypes": [
      "Lung cancer (screening enhancement - pre-LDCT risk stratification)"
    ],
    "targetPopulation": "USPSTF-eligible: Adults 50-80 years; ≥20 pack-years smoking history; current smokers or quit within 15 years",
    "indicationGroup": "Lung",
    "sensitivity": 80,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageISensitivity": 71,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIISensitivity": 89,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIIISensitivity": 88,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "stageIVSensitivity": 98,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "specificity": 58,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "ppv": 1.3,
    "ppvCitations": "DELFI Diagnostics brochure (derived from NNS 79)",
    "ppvNotes": "Derived from Number Needed to Screen (NNS): brochure states 79 people with Elevated result need LDCT to find 1 lung cancer, implying PPV ≈ 1/79 ≈ 1.27%",
    "ppvDefinition": "PPV for lung cancer among Elevated results in high-risk USPSTF screening population",
    "npv": 99.7,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/38829053/",
    "npvDefinition": "NPV for being lung-cancer free among Not Elevated results in high-risk USPSTF screening population",
    "performanceCitations": "DELFI-L101 Cancer Discovery 2024 (n=958); CASCADE-LUNG/L201 (NCT05306288); FIRSTLung/L301 (NCT06145750)",
    "performanceNotes": "80% overall sensitivity (71% Stage I; 98% Stage IV); 58% specificity; 99.7% NPV; fragmentomics approach novel mechanism.",
    "leadTimeNotes": "Pre-LDCT risk stratification; 5.5× higher cancer likelihood with Elevated result; designed to increase LDCT uptake (currently only 6% eligible adults screened)",
    "fdaStatus": "LDT; FDA IVD submission planned",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not established; not covered by Medicare",
    "clinicalAvailability": "Early Experience Program at select health systems (OSF HealthCare; City of Hope; Indigenous Pact)",
    "tat": "10-14 business days",
    "sampleType": "Standard blood draw",
    "sampleVolume": "<1 mL plasma required",
    "sampleStability": "Standard",
    "cptCode": "UNKNOWN",
    "listPrice": 300,
    "screeningInterval": "Annual (complement to LDCT)",
    "clinicalTrials": "NCT05306288 CASCADE-LUNG prospective validation (15000 target); NCT04825834 DELFI-L101 case-control development (958); NCT06145750 FIRSTLung cluster RCT (ongoing)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05306288 | https://clinicaltrials.gov/study/NCT04825834 | https://clinicaltrials.gov/study/NCT06145750",
    "totalParticipants": 15958,
    "numPublications": 3,
    "numPublicationsPlus": true
  },
  {
    "id": "ecd-8",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.heliogenomics.com/",
    "name": "HelioLiver",
    "vendor": "Helio Genomics",
    "testScope": "Single-cancer (HCC/Liver)",
    "approach": "Blood-based cfDNA methylation + protein biomarkers",
    "method": "AI algorithm analyzing cfDNA methylation patterns + AFP + AFP-L3 + DCP + demographics",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults with cirrhosis; chronic HBV carriers; high-risk for HCC",
    "indicationGroup": "Liver",
    "sensitivity": 47.8,
    "sensitivityCitations": "CLiMB study EASL 2024 (NCT03694600); https://heliogenomics.com/climb-study/",
    "sensitivityNotes": "CLiMB prospective study (n=1,968): 47.8% overall HCC, 37.8% for HCC ≤4cm, 28.6% for HCC <2cm. Earlier case-control ENCORE study (n=247) reported 85% sensitivity; prospective real-world performance is materially lower. CLiMB used contemporaneous MRI on all subjects.",
    "stageISensitivity": 37.8,
    "stageISensitivityCitations": "CLiMB study EASL 2024 (NCT03694600)",
    "stageISensitivityNotes": "37.8% for HCC ≤4cm; 28.6% for HCC <2cm; 44.4% for T1 tumors (vs 11.1% for ultrasound)",
    "specificity": 88,
    "specificityCitations": "CLiMB study EASL 2024; Helio Genomics investor deck",
    "specificityNotes": "88% specificity (95% CI: 86-89) from CLiMB prospective study and Helio investor materials. Earlier ENCORE case-control reported 91%.",
    "ppv": 76,
    "ppvCitations": "Helio Genomics Investor Data; high-risk cirrhotic surveillance population",
    "ppvNotes": "PPV 76% in high-risk (cirrhotic) surveillance population. Higher PPV than general screening tests due to elevated HCC prevalence in cirrhosis patients (~1-8%/year).",
    "ppvDefinition": "PPV for hepatocellular carcinoma (HCC) in high-risk surveillance population (cirrhosis / chronic HBV)",
    "npv": 98,
    "npvCitations": "Helio Genomics Investor Data",
    "npvNotes": "NPV 98% - negative result reliably rules out HCC in surveillance population",
    "npvDefinition": "NPV for absence of HCC in high-risk surveillance population (cirrhosis / chronic HBV)",
    "listPrice": 525,
    "listPriceCitations": "Helio Genomics; estimated range $450-$600",
    "listPriceNotes": "Estimated price ~$450-$600 based on market positioning",
    "performanceCitations": "ENCORE Hepatology Communications 2022 (n=247); CLiMB EASL 2024 (n=1968); VICTORY (n=1100)",
    "performanceNotes": "CLiMB prospective (n=1,968): 47.8% overall, 37.8% early-stage. Case-control ENCORE (n=247) showed higher 85%/76% but prospective real-world data is more reliable. Still outperforms ultrasound (11.1% T1 detection).",
    "leadTimeNotes": "Significantly outperforms ultrasound for early-stage HCC detection (44.4% vs 11.1% for T1 tumors); designed as surveillance tool",
    "fdaStatus": "PMA submitted Q2 2024 (Class III); currently LDT",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Expected upon FDA approval; CPT code 0333U assigned",
    "clinicalAvailability": "Commercially available as LDT",
    "tat": "10-14 days",
    "tatNotes": "Estimated 10-14 days based on similar multi-analyte blood tests",
    "sampleType": "Blood (serum for proteins; plasma for cfDNA)",
    "sampleVolume": "Standard blood draw",
    "sampleStability": "Standard",
    "cptCode": "0333U",
    "screeningInterval": "Every 6 months (per AASLD)",
    "clinicalTrials": "NCT05059665 ENCORE validation (247); NCT03694600 CLiMB prospective HCC surveillance (1968); VICTORY study (1100)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05059665 | https://clinicaltrials.gov/study/NCT03694600",
    "totalParticipants": 3315,
    "numPublications": 2,
    "numPublicationsPlus": true,
    "vendorRequestedChanges": "2026-01-11: Updated sensitivity from 85% to 47.8% and stage I from 76% to 37.8% per CLiMB prospective study (n=1,968) data presented at EASL 2024. Previous ENCORE case-control data (n=247) overstated performance. Error report submitted by Pierre Arsene (Mursla). 2026-01-12: Corrected specificity from 91% to 88% per CLiMB/Helio investor deck (Pierre Arsene follow-up)."
  },
  {
    "id": "ecd-9",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.exactsciences.com/",
    "name": "Oncoguard Liver",
    "vendor": "Exact Sciences",
    "testScope": "Single-cancer (HCC/Liver)",
    "approach": "Blood-based methylated DNA markers + protein",
    "method": "3 methylated DNA markers (HOXA1; EMX1; TSPYL5) + AFP + biological sex; LQAS PCR technology; developed with Mayo Clinic",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults with cirrhosis; chronic HBV; high-risk for HCC requiring surveillance",
    "indicationGroup": "Liver",
    "sensitivity": 70,
    "sensitivityCitations": "ALTUS study AASLD November 2025 (NCT05064553); Exact Sciences AASLD 2025 presentation",
    "sensitivityNotes": "ALTUS prospective study (n=2,206): 70% overall sensitivity. Milan criteria sensitivity 66.7% (vs 22.2% ultrasound). By tumor size: 58.3% for <2cm, 78.3% for 2-5cm, 75% for 5+cm. Earlier press release cited 77% which may have been preliminary/typo per AASLD presentation data.",
    "stageISensitivity": 64,
    "stageISensitivityCitations": "ALTUS study AASLD November 2025 (NCT05064553)",
    "stageISensitivityNotes": "64% very early-stage HCC (vs 9% for ultrasround - 7× improvement); 77% for Milan criteria early-stage (vs 36% for ultrasound)",
    "specificity": 81.9,
    "specificityCitations": "ALTUS study AASLD November 2025 (NCT05064553); Exact Sciences AASLD 2025 presentation",
    "specificityNotes": "81.9% specificity in ALTUS (n=2,206) vs 87% in Phase II case-control. Ultrasound alone: 98.6% specificity; Ultrasound+AFP: 97.7%.",
    "ppv": 37.5,
    "ppvCitations": "Oncoguard Liver FAQ; Exact Sciences clinical data",
    "ppvNotes": "PPV 35-40% in high-risk HCC surveillance population. Moderate PPV reflects balance of sensitivity (77%) with specificity (82%) in cirrhotic patients.",
    "ppvDefinition": "PPV for HCC in high-risk surveillance population (ALTUS / validation cohorts)",
    "npv": 98.5,
    "npvCitations": "Oncoguard Liver FAQ; Exact Sciences clinical data",
    "npvNotes": "NPV 98-99% - negative result reliably rules out HCC",
    "npvDefinition": "NPV for absence of HCC in high-risk surveillance population (ALTUS / validation cohorts)",
    "listPrice": 600,
    "listPriceCitations": "Estimated based on market positioning; Medicare not covered",
    "listPriceNotes": "Estimated ~$500-$700. NOT covered by Medicare; financial assistance available.",
    "performanceCitations": "Phase II validation CGH 2021; ALTUS NCT05064553 (n>3000) November 2025",
    "performanceNotes": "ALTUS prospective (n=3,000+): 77% early-stage, 64% very early-stage, 82% specificity. Phase II case-control showed higher 88%/82%/87% but prospective real-world data is more reliable. Still 2-7× ultrasound detection rates.",
    "leadTimeNotes": "ALTUS study shows 77% early-stage vs 36% for ultrasound; 64% very early-stage vs 9% for ultrasound (6-7× improvement)",
    "fdaStatus": "LDT; Breakthrough Device Designation October 2019",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "NOT covered by Medicare; financial assistance available (1-844-870-8870)",
    "clinicalAvailability": "Commercially available",
    "tat": "~1 week",
    "sampleType": "Blood (Exact Sciences collection kit)",
    "sampleVolume": "Standard blood draw",
    "sampleStability": "Standard",
    "cptCode": "81599",
    "screeningInterval": "Every 3-6 months",
    "clinicalTrials": "NCT05064553 ALTUS prospective HCC surveillance (3000+); Phase II validation CGH 2021",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05064553",
    "totalParticipants": 3000,
    "numPublications": 3,
    "numPublicationsPlus": true,
    "vendorRequestedChanges": "2026-01-11: Updated sensitivity from 88% to 77% (early-stage) and 82% to 64% (very early-stage), specificity from 87% to 82% per ALTUS prospective study (n=3,000+) presented at AASLD November 2025. Previous Phase II case-control data overstated performance. Error report submitted by Pierre Arsene (Mursla). 2026-01-12: Further corrected sensitivity from 77% to 70% overall per AASLD 2025 presentation charts; specificity refined to 81.9% (Pierre Arsene follow-up with screenshots)."
  },
  {
    "id": "ecd-10",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 40,
    "sampleTubeType": "Guardant cfDNA BCT",
    "sampleTubeCount": 4,
    "sampleCitations": "https://www.guardanthealth.com/",
    "name": "Shield MCD",
    "vendor": "Guardant Health",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Methylation-based NGS cfDNA platform detecting 10 cancer types; same Shield platform as CRC test with expanded analysis; requires physician opt-in and patient authorization for EMR data release",
    "cancerTypes": [
      "Bladder; Colorectal; Esophageal; Gastric; Liver; Lung; Ovarian; Pancreas; Breast; Prostate (10 tumor types)"
    ],
    "targetPopulation": "Average-risk adults 45+ years; ordered as add-on when physician requests Shield CRC test",
    "indicationGroup": "MCED",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Cancer signal of origin prediction included; specific accuracy not yet publicly disclosed; performance data presented at AACR/ASCO 2025",
    "sensitivity": 60,
    "sensitivityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",
    "sensitivityNotes": "Overall episode-based sensitivity ~60% across all 10 cancer types; ~74% sensitivity for subset of deadliest/aggressive cancers. Data from interim MCED performance presented at AACR/ASCO 2025.",
    "sensitivityType": "episode-based interim",
    "specificity": 98.5,
    "specificityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/Guardant-Health-Presents-Data-Demonstrating-Strong-Performance-of-Shield-Multi-Cancer-Detection-Test-Across-10-Tumor-Types/default.aspx",
    "specificityNotes": "~98.5% specificity from interim Shield MCED data. High specificity critical for screening use to minimize false positives.",
    "ppv": 3.1,
    "ppvCitations": "Guardant Health Shield HCP Page; based on MCED screening population",
    "ppvNotes": "PPV ~3.1% in screening population. Low PPV expected for MCED tests in average-risk populations due to low individual cancer prevalences.",
    "ppvDefinition": "PPV for any of 10 target cancers among positive Shield MCD results",
    "npv": 99.9,
    "npvCitations": "Guardant Health Shield HCP Page",
    "npvNotes": "NPV 99.9% - negative result strongly rules out the 10 target cancers",
    "npvDefinition": "NPV for remaining cancer-free among negative Shield MCD results",
    "listPrice": 895,
    "listPriceCitations": "Medicare reimbursement rate; Guardant Health",
    "listPriceNotes": "Priced at ~$895 consistent with Shield CRC Medicare coverage; no additional charge when ordered as add-on to Shield CRC",
    "performanceCitations": "AACR 2025 oral presentation; ASCO 2025; NCI Vanguard Study (NCT pending; n=24000); Guardant Health Investor Relations 2025",
    "performanceNotes": "Overall sensitivity ~60% across all cancers; ~74% sensitivity for subset of deadliest cancers; ~98.5% specificity. Performance data from interim MCED analysis supported NCI selection for Vanguard Study.",
    "leadTimeNotes": "Available as add-on to Shield CRC screening; physician must opt-in and patient must authorize release of medical records to Guardant in exchange for MCD results",
    "fdaStatus": "LDT; FDA Breakthrough Device Designation (June 2025); selected for NCI Vanguard Study (24000 participants); Shield MCD reviewed by FDA as part of NCI investigational device exemption (IDE)",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Not covered by Medicare or commercial payers; no additional cost when ordered with Shield CRC (data exchange model)",
    "clinicalAvailability": "Launched nationally October 2025; available when ordering Shield CRC test with physician opt-in",
    "availableRegions": [
      "US"
    ],
    "tat": "~14 days (same blood draw as Shield CRC)",
    "sampleType": "Whole blood in Guardant cfDNA BCT tubes (same sample as Shield CRC)",
    "sampleVolume": "4 tubes (no additional blood draw required)",
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "UNKNOWN",
    "screeningInterval": "Annual recommended (with Shield CRC every 3 years)",
    "clinicalTrials": "NCI Vanguard Study multi-cancer detection feasibility (24000 target); AACR 2025 presentations; ASCO 2025 presentations",
    "totalParticipants": 24000,
    "numPublications": 0
  },
  {
    "id": "ecd-11",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 20,
    "sampleTubeType": "Streck cfDNA BCT",
    "sampleTubeCount": 2,
    "name": "EPISEEK",
    "vendor": "Precision Epigenomics",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Methylation-specific PCR detecting hypermethylated cfDNA loci across 60+ cancer types including all 20 most fatal cancers; does not use NGS; analyzes 10 cancer biomarkers",
    "cancerTypes": [
      "60+ cancer types including all 20 most fatal cancers: lung, liver, pancreas, esophageal, bladder, stomach, head & neck SCC, uterine, low-grade glioma, high-grade glioma (brain cancer detection believed unique among blood-based MCED tests)"
    ],
    "targetPopulation": "Adults 45+ years with elevated cancer risk; can be considered from age 21 with risk factors (smoking, family history)",
    "indicationGroup": "MCED",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Does not predict tissue of origin (no CSO/TOO); requires standard diagnostic workup to localize cancer source",
    "sensitivity": 54,
    "sensitivityCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "sensitivityNotes": "Overall incidence-adjusted sensitivity (IAS) across all stages. IAS is more conservative than observed sensitivity as it weights by cancer incidence.",
    "stageISensitivity": 45,
    "stageISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageIISensitivity": 45,
    "stageIISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageISensitivityNotes": "Combined Stage I/II IAS = 45%. For aggressive unscreened cancers (bladder, esophagus, liver, H&N, lung, pancreas, stomach, uterine) Stage I/II sensitivity is 57%.",
    "stageIIISensitivity": 73,
    "stageIIISensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "stageIVSensitivity": 74,
    "stageIVSensitivityCitations": "https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "specificity": 99.5,
    "specificityCitations": "https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3144 | https://precision-epigenomics.com/precision-epigenomics-presents-validation-of-episeek-a-multi-cancer-early-detection-test-at-2025-asco-annual-meeting/",
    "ppv": 64.9,
    "ppvCitations": "https://www.prnewswire.com/news-releases/precision-epigenomics-launches-episeek-the-first-blood-based-multi-cancer-screening-test-for-men-302012353.html",
    "ppvDefinition": "PPV in validation cohort (n=482). Modeled PPV of 40% in screening population age 50+.",
    "npv": 99.5,
    "npvCitations": "https://www.prnewswire.com/news-releases/precision-epigenomics-launches-episeek-the-first-blood-based-multi-cancer-screening-test-for-men-302012353.html",
    "npvDefinition": "NPV for absence of cancer in validation cohort",
    "performanceCitations": "Pham TH et al. J Clin Oncol 2025;43(16_suppl):3144. ASCO 2025 Annual Meeting.",
    "performanceNotes": "Validation included 281 cancer-positive plasma samples across all stages and 201 healthy controls age 40+. Analytical LOD <0.1 ng cfDNA for 8/10 biomarkers. Uses incidence-adjusted sensitivity (more conservative than observed sensitivity).",
    "leadTimeNotes": "No lead time vs imaging data reported; designed for asymptomatic screening",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial insurance coverage. Positioned as affordable/accessible alternative to NGS-based MCED tests.",
    "commercialPayers": [],
    "clinicalAvailability": "Commercially available in US via CLIA-certified lab in Tucson, AZ. Physician-ordered (not direct-to-consumer).",
    "availableRegions": [
      "US"
    ],
    "tat": "5 days",
    "tatNotes": "Collection to report turnaround time (includes shipping and processing). Lab processing time is 2-3 days.",
    "sampleType": "Two 10-mL Streck cfDNA BCT tubes",
    "sampleVolume": "20 mL whole blood (two 10-mL tubes)",
    "cptCode": "UNKNOWN",
    "listPrice": 699,
    "screeningInterval": "Not specified",
    "clinicalTrials": "ASCO 2025 validation study (n=482); simulated 100,000-patient SEER-based screening cohort modeling",
    "totalParticipants": 482,
    "numPublications": 1,
    "numPublicationsPlus": false,
    "technologyDifferentiator": "PCR-based (not NGS) - enables faster TAT, lower cost, and global scalability vs sequencing-based MCED tests"
  },
  {
    "id": "ecd-12",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "ProVue Lung",
    "vendor": "PrognomiQ",
    "testScope": "Single-cancer (Lung)",
    "approach": "Blood-based proteomics",
    "method": "Proteomics-based analysis using proprietary multi-omics platform to detect unique molecular protein signatures of lung cancer; does not analyze ctDNA or methylation",
    "cancerTypes": [
      "Lung cancer (all types)"
    ],
    "targetPopulation": "High-risk adults aged 50+ with 20+ pack-year smoking history; consistent with USPSTF, ACS, and NCCN lung cancer screening guidelines",
    "indicationGroup": "Lung",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; lung-specific",
    "sensitivity": 85,
    "sensitivityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",
    "sensitivityNotes": "Overall sensitivity for all stages of lung cancer",
    "stageISensitivity": 81,
    "stageISensitivityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html",
    "stageISensitivityNotes": "Stage I sensitivity when treatment is most effective",
    "specificity": 55,
    "specificityCitations": "https://www.globenewswire.com/news-release/2025/11/18/3190424/0/en/UPDATE-PrognomiQ-Launches-ProVue-Lung-a-Proteomics-Based-Laboratory-Developed-Test-to-Aid-in-the-Early-Detection-of-Lung-Cancer.html | https://prognomiq.com/provue/",
    "specificityNotes": "Lower specificity results in higher false positive rate; designed as adjunct to LDCT screening",
    "npv": 99.8,
    "npvCitations": "https://prognomiq.com/insights/provue-lung/",
    "npvNotes": "NPV >99.8% indicates strong rule-out capability. High NPV despite lower specificity.",
    "ppv": 44,
    "ppvCitations": "PrognomiQ clinical data; high-risk smoking population",
    "ppvNotes": "PPV ~44% in high-risk screening population (50+ years, 20+ pack-year smoking history). Moderate PPV reflects trade-off for high sensitivity.",
    "ppvDefinition": "PPV for lung cancer in high-risk screening population",
    "npvDefinition": "NPV for absence of lung cancer in high-risk screening population",
    "performanceCitations": "Unpublished data on file; manuscript under preparation. PrognomiQ website and press release Nov 2025.",
    "performanceNotes": "Validated in multiple prospective case-control studies. Binary result (ELEVATED or NOT ELEVATED). 85% sensitivity all-stage, 81% Stage I, 55% specificity, >99.8% NPV.",
    "leadTimeNotes": "Designed as adjunct to low-dose CT (LDCT); aims to improve screening compliance (currently <16% of eligible patients undergo annual LDCT)",
    "fdaStatus": "CLIA LDT – NOT FDA approved",
    "fdaStatusNotes": "Laboratory is CLIA-certified and CAP-accredited. Not cleared or approved by FDA.",
    "reimbursement": "Self-Pay",
    "reimbursementNote": "No Medicare or commercial insurance coverage established. Available through Early Experience Program.",
    "commercialPayers": [],
    "clinicalAvailability": "Limited availability - Early Experience Program at select Pennsylvania health systems (Allegheny Health Network, Penn Highlands Healthcare Lung Innovations Network). Launched November 18, 2025.",
    "clinicalAvailabilityNotes": "Initial commercial launch through Early Experience Program to evaluate clinical workflow integration. Broader availability expected as program expands.",
    "tat": "7-10 days",
    "tatNotes": "Estimated 7-10 days based on proteomics platform; specific TAT not publicly disclosed",
    "sampleType": "Blood (simple blood draw)",
    "sampleVolume": "Standard blood draw",
    "cptCode": "UNKNOWN",
    "listPrice": 800,
    "listPriceCitations": "Estimated based on market positioning",
    "listPriceNotes": "Estimated ~$800. Self-pay only; no Medicare or commercial insurance coverage.",
    "screeningInterval": "Not specified; designed to complement annual LDCT screening",
    "clinicalTrials": "Multiple prospective case-control validation studies (unpublished); Early Experience Program at Allegheny Health Network and Penn Highlands Healthcare",
    "totalParticipants": null,
    "totalParticipantsNotes": "Validation study size not publicly disclosed; manuscript under preparation",
    "numPublications": 0,
    "numPublicationsPlus": false,
    "numPublicationsNotes": "Manuscript under preparation; data presented on company website",
    "technologyDifferentiator": "Proteomics-based (not ctDNA/methylation) - first protein-based liquid biopsy for lung cancer detection; measures protein biomarkers rather than genetic or epigenetic signals; simple blood draw with no specialized collection tubes"
  },
  {
    "id": "ecd-13",
    "sampleCategory": "Blood/Plasma",
    "name": "Signal-C",
    "vendor": "Universal DX",
    "testScope": "Single-cancer (CRC)",
    "approach": "cfDNA methylation + fragmentation",
    "method": "Next-generation sequencing (NGS) analyzing cell-free DNA methylation patterns and fragmentation characteristics; multi-omics approach combining methylomics, fragmentomics, and machine learning algorithms to detect colorectal cancer and advanced adenomas from a single blood draw",
    "cancerTypes": [
      "Colorectal cancer (CRC)",
      "Advanced adenomas (pre-cancerous)"
    ],
    "targetPopulation": "Average-risk adults aged 45+ eligible for colorectal cancer screening per USPSTF guidelines",
    "indicationGroup": "CRC",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; colorectal-specific",
    "sensitivity": 93,
    "sensitivityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics|https://www.universaldx.com/science",
    "sensitivityNotes": "93% sensitivity for CRC detection in 1,000-patient multi-cohort study presented at DDW 2023. Company website reports 92% sensitivity with 94% specificity in some materials - slight variations across presentations.",
    "stageISensitivity": 91,
    "stageISensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageISensitivityNotes": "91% (21/23) Stage I sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "stageIISensitivity": 92,
    "stageIISensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageIISensitivityNotes": "92% (23/25) Stage II sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "stageIIISensitivity": 91,
    "stageIIISensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageIIISensitivityNotes": "91% (30/33) Stage III sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "stageIVSensitivity": 93,
    "stageIVSensitivityCitations": "https://www.businesswire.com/news/home/20230120005048/en/",
    "stageIVSensitivityNotes": "93% (13/14) Stage IV sensitivity from international observational cohort study. Source: Universal DX Business Wire press release (Jan 2023), not peer-reviewed.",
    "advancedAdenomaSensitivity": 54,
    "advancedAdenomaSensitivityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://newsroom.questdiagnostics.com/2023-11-20-Universal-DX-Announces-Strategic-Collaboration-with-Quest-Diagnostics",
    "advancedAdenomaSensitivityNotes": "54% sensitivity for advanced adenomas at 92% specificity. This pre-cancer detection capability is a key differentiator - may help prevent CRC, not just detect it.",
    "specificity": 92,
    "specificityCitations": "https://www.businesswire.com/news/home/20230509005536/en | https://www.universaldx.com/science",
    "specificityNotes": "92% specificity in DDW 2023 study. Some company materials report 94% specificity - may reflect different cohorts or thresholds.",
    "ppv": 6,
    "ppvCitations": "Calculated from sensitivity/specificity at 0.5% CRC prevalence | https://www.universaldx.com/science",
    "ppvNotes": "Estimated ~6% PPV at 0.5% CRC prevalence in average-risk screening population. Actual PPV will depend on screening population prevalence.",
    "npv": 99.9,
    "npvCitations": "Calculated from sensitivity/specificity at 0.5% CRC prevalence | https://www.universaldx.com/science",
    "npvNotes": "Estimated ~99.9% NPV at 0.5% CRC prevalence. High NPV provides strong negative predictive value for ruling out CRC.",
    "performanceCitations": "DDW 2023 presentation; ASCO GI 2023 presentation; https://www.universaldx.com/science",
    "performanceNotes": "Large 1,000-patient international multi-cohort case-control study with prospectively collected samples from US and Europe. Performance validated across multiple presentations at ASCO GI 2023 and DDW 2023.",
    "leadTimeNotes": "Blood-based alternative to colonoscopy and stool-based tests; aims to increase screening compliance among the ~40% of eligible adults not up-to-date on CRC screening",
    "fdaStatus": "Investigational – FDA pivotal trial ongoing",
    "fdaStatusCitations": "https://clinicaltrials.gov/study/NCT06059963 | https://www.businesswire.com/news/home/20240807274324/en/Universal-DX-Initiates-Clinical-Trial-for-FDA-Approval-of-Signal-C-Colorectal-Cancer-Screening-Blood-Test",
    "fdaStatusNotes": "FDA premarket approval (PMA) pivotal trial initiated January 2024. Targeting enrollment of 15,000+ patients across 100 investigator sites. Quest Diagnostics oncology center in Lewisville, TX serves as single testing site for trial.",
    "reimbursement": "Not yet established",
    "reimbursementNote": "Pending FDA approval; not currently available for clinical use in US",
    "commercialPayers": [],
    "clinicalAvailability": "Not yet commercially available – FDA pivotal trial in progress",
    "clinicalAvailabilityNotes": "Quest Diagnostics has exclusive US commercialization rights pending FDA approval (collaboration announced November 2023). Commercial launch expected following PMA approval.",
    "tat": "Not specified",
    "tatNotes": "Turnaround time not publicly disclosed; will be determined for commercial launch",
    "sampleType": "Blood (single draw)",
    "sampleVolume": "Not specified",
    "cptCode": "TBD",
    "cptCodesNotes": "CPT code to be established upon FDA approval and commercial launch",
    "listPrice": null,
    "listPriceNotes": "Pricing not yet established; pending FDA approval",
    "screeningInterval": "Not specified; likely aligned with standard CRC screening intervals (every 3 years typical for blood-based tests)",
    "clinicalTrials": "FDA pivotal trial (NCT06059963) - 15,000+ patient enrollment target across 100 sites; prior 1,000-patient validation study",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06059963",
    "totalParticipants": 1000,
    "totalParticipantsNotes": "1,000 patients in published validation study (DDW 2023); 15,000+ targeted for ongoing FDA pivotal trial",
    "numPublications": 3,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Multiple conference presentations at DDW 2023, ASCO GI 2023, AACR 2022; peer-reviewed publications in preparation",
    "technologyDifferentiator": "Multi-omics approach combining methylation + fragmentation analysis with machine learning. Company claims to have identified specific cfDNA sequence regions that capture cancer's earliest signals. Spain-based biotech (Universal DX) with US office in Cambridge, MA. Platform technology (Signal-X) being extended to other GI cancers including pancreatic, liver, and gastric."
  },
  {
    "id": "ecd-14",
    "sampleCategory": "Stool",
    "sampleVolumeG": 15,
    "sampleVolumeMin": 10,
    "sampleTubeCount": 4,
    "name": "IColocomf",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool DNA methylation",
    "method": "Fluorescent quantitative PCR detection of methylated SDC2 and TFPI2 genes in intestinal exfoliated cells from stool samples. Dual-target methylation-specific PCR with bisulfite conversion.",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "Individuals assessed by physician as needing colonoscopy screening; high-risk CRC screening population",
    "indicationGroup": "CRC",
    "sensitivity": 95.31,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "sensitivityNotes": "95.31% overall CRC sensitivity from multicenter clinical trial (n=1,164) published in J Mol Diagn 2022. Independent academic study - vendor did not participate in experimental research.",
    "stageISensitivity": 96.93,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageISensitivityNotes": "Stage I-II combined: 96.93% (158/163 detected). Individual stage I data not separately reported.",
    "stageIISensitivity": 96.93,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageIISensitivityNotes": "Stage I-II combined: 96.93% (158/163 detected)",
    "stageIIISensitivity": 93.06,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageIIISensitivityNotes": "Stage III-IV combined: 93.06% (134/144 detected)",
    "stageIVSensitivity": 93.06,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "stageIVSensitivityNotes": "Stage III-IV combined: 93.06% (134/144 detected)",
    "advancedAdenomaSensitivity": 63.16,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "advancedAdenomaSensitivityNotes": "63.16% sensitivity for advanced adenomas (n=38); 33.64% for non-advanced adenomas (n=110)",
    "specificity": 96.67,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "specificityNotes": "96.67% specificity vs healthy controls (n=300). 93.15% specificity when including interfering diseases (other GI conditions). 88.39% specificity vs all non-CRC participants.",
    "ppv": 75.68,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "ppvNotes": "75.68% PPV for CRC in study population",
    "npv": 98.03,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/",
    "npvNotes": "98.03% NPV for CRC in study population",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/34890778/ | https://pubmed.ncbi.nlm.nih.gov/35227195/ | https://pubmed.ncbi.nlm.nih.gov/33958894/ | https://pubmed.ncbi.nlm.nih.gov/35004840/",
    "performanceNotes": "Multicenter, double-blinded, case-control study across 3 hospitals (Peking Union Medical College Hospital, First Affiliated Hospital of Anhui Medical University, Zhongnan Hospital of Wuhan University). 1,164 participants including 320 CRC, 148 adenomas, 396 interfering diseases, 300 healthy controls. Authors declare no conflict of interest; company did not participate in research.",
    "leadTimeNotes": "Noninvasive stool-based alternative to colonoscopy for CRC screening in high-risk populations",
    "fdaStatus": "NMPA approved (China, 2022); CE-IVD (EU, 2021)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA) in 2022. CE marked for European market in 2021. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": [
      "China",
      "EU"
    ],
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results",
    "sampleType": "Fresh stool sample (10-15g) in preservative buffer",
    "sampleVolume": "10-15g stool in 45mL tube with 30mL preservative",
    "cptCode": "N/A (not US market)",
    "listPrice": 500,
    "listPriceNotes": "Approximately $500 USD equivalent",
    "screeningInterval": "Per physician recommendation",
    "clinicalTrials": "ChiCTR2100050110 - multicenter clinical validation trial (1,164 participants)",
    "clinicalTrialsCitations": "https://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100050110",
    "totalParticipants": 1164,
    "numPublications": 4,
    "numPublicationsNotes": "4 peer-reviewed publications including J Mol Diagn 2022 multicenter validation study",
    "technologyDifferentiator": "Dual-target stool DNA methylation test combining SDC2 and TFPI2 markers. SDC2 shows higher specificity, TFPI2 shows higher sensitivity - combination improves overall detection. Complementary methylation patterns for left-sided (TFPI2) vs right-sided (SDC2) colon cancers. First Chinese stool DNA methylation test in OpenOnco database."
  },
  {
    "id": "ecd-15",
    "sampleCategory": "Urine",
    "sampleVolumeMl": 50,
    "sampleVolumeMin": 30,
    "sampleCitations": "https://nonacus.com/",
    "name": "GALEAS Bladder",
    "vendor": "Nonacus",
    "testScope": "Single-cancer (Bladder)",
    "approach": "Urine-based targeted NGS",
    "method": "Ultra-deep targeted NGS of urinary DNA targeting promoter and exonic regions of 23 genes associated with bladder cancer. Detects 451 somatic mutations covering 96% of bladder cancers. Uses Cell3 Target enrichment technology with Illumina sequencing at 5M read depth per sample.",
    "cancerTypes": [
      "Bladder cancer (urothelial carcinoma)"
    ],
    "targetPopulation": "Symptomatic patients with hematuria undergoing diagnostic workup; designed as cystoscopy alternative for hematuria triage, not asymptomatic population screening",
    "indicationGroup": "Bladder",
    "sensitivity": 90,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/",
    "sensitivityNotes": ">90% sensitivity across all grades and stages of bladder cancer, equivalent to cystoscopy. Validated in >700 patient samples from 3 UK clinical cohorts (384 bladder cancer cases, 388 negative controls).",
    "specificity": 85,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/",
    "specificityNotes": ">85% specificity. Performance equivalent to cystoscopy for all grades and stages including non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC).",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/ | https://pubmed.ncbi.nlm.nih.gov/31125144/",
    "performanceNotes": "High diagnostic accuracy demonstrated in Ward et al. European Urology Oncology 2023 validation study. Performance equivalent to cystoscopy with potential to reduce cystoscopies by ~90%. Additional validation in Ward et al. BJU International 2019 (23-gene panel development).",
    "ppv": 52,
    "ppvCitations": "Nonacus GALEAS Product Page; hematuria triage population",
    "ppvNotes": "PPV ~52% in symptomatic hematuria triage population. Higher PPV than screening tests due to elevated disease prevalence in symptomatic patients.",
    "npv": 99,
    "npvCitations": "Nonacus GALEAS Product Page",
    "npvNotes": "NPV 99% - negative result strongly rules out bladder cancer in hematuria patients",
    "leadTimeNotes": "Non-invasive urine-based alternative to cystoscopy for hematuria workup. Designed to streamline diagnosis and reduce need for invasive procedures.",
    "fdaStatus": "UKCA marked (UK); CE-IVDR pending (EU application submitted); US availability planned via LDT route (CAP/CLIA lab)",
    "fdaStatusNotes": "Currently UKCA marked in accordance with UK Medical Devices Regulations 2002. CE-IVDR application submitted. US market entry planned via LDT pathway through CAP/CLIA certified laboratory.",
    "reimbursement": "Private pay (UK)",
    "reimbursementNote": "Currently available privately in the UK. NHS adoption emerging. US reimbursement to be determined following LDT availability.",
    "commercialPayers": [],
    "availableRegions": [
      "UK"
    ],
    "clinicalAvailability": "Commercially available in UK (private); US availability anticipated via LDT route",
    "tat": "7-14 days",
    "tatNotes": "Cloud-based analysis; typical 7-14 days depending on laboratory workflow",
    "listPrice": 750,
    "listPriceCitations": "Estimated based on market positioning ($600-$900 range)",
    "listPriceNotes": "Estimated ~$600-$900. Private pay in UK; US pricing TBD.",
    "sampleType": "Urine (cell pellet genomic DNA from urinary cell pellet)",
    "sampleVolume": "30-50 mL urine",
    "sampleVolumeNotes": "Home collection kit available. Sample returned in 50mL tube with proprietary preservative.",
    "cptCode": "N/A (not yet US market)",
    "clinicalTrials": "Additional hematuria setting trials ongoing (2 studies); real-world evidence study in surveillance setting planned",
    "clinicalTrialsCitations": "https://pubmed.ncbi.nlm.nih.gov/36335043/",
    "totalParticipants": 772,
    "totalParticipantsNotes": "Validation cohort: >700 samples from 3 UK clinical cohorts including 384 bladder cancer cases and 388 negative controls",
    "numPublications": 2,
    "numPublicationsNotes": "Ward et al. European Urology Oncology 2023; Ward et al. BJU International 2019",
    "technologyDifferentiator": "First urine-based bladder cancer test in OpenOnco database. 23-gene NGS panel developed in collaboration with University of Birmingham Bladder Cancer Research Centre. Unique home collection option with barcode traceability. Potential for use across entire bladder cancer care pathway including hematuria triage, NMIBC/MIBC surveillance, and MRD monitoring.",
    "vendorRequestedChanges": "2025-12-15: Added at vendor request (Chris Sale, CSO). Confirmed test is for symptomatic hematuria patients (diagnostic workup), not asymptomatic screening. Currently UKCA marked; CE-IVDR pending; US LDT route planned. Additional trial data expected from 2 hematuria studies + real-world surveillance study."
  },
  {
    "id": "ecd-21",
    "sampleCategory": "Blood/Plasma",
    "name": "OverC Multi-Cancer Detection Blood Test",
    "vendor": "Burning Rock Dx (brbiotech)",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA methylation MCED (plasma)",
    "method": "Tumor-naïve cfDNA methylation profiling (ELSA-seq) with targeted NGS + machine-learning classifier; predicts cancer signal and tissue of origin (TPO)",
    "cancerTypes": [
      "Colorectal",
      "Esophageal",
      "Liver",
      "Lung",
      "Ovarian",
      "Pancreatic"
    ],
    "targetPopulation": "Adults 50-75 years at average risk for cancer",
    "indicationGroup": "MCED",
    "sensitivity": 69.1,
    "sensitivityCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext",
    "sensitivityNotes": "69.1% overall sensitivity (MCDBT-1 model) across 6 cancer types in THUNDER study independent validation cohort (n=473 cancer, 473 non-cancer). Adjusted sensitivity 70.6% when weighted by China cancer incidence.",
    "stageISensitivity": null,
    "stageISensitivityNotes": "Overall stage I sensitivity not reported. Liver cancer stage-specific: Stage I 77.3%, Stage II 81.8%, Stage III 95.0%. Lung cancer: 52-81% across stages IA-III.",
    "stageIISensitivity": null,
    "stageIIISensitivity": null,
    "stageIVSensitivity": null,
    "specificity": 98.9,
    "specificityCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext",
    "specificityNotes": "98.9% specificity in THUNDER independent validation cohort.",
    "ppv": 12.3,
    "ppvCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "npv": 99.9,
    "npvCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "tumorOriginAccuracy": 83.2,
    "tumorOriginAccuracyNotes": "Cancer Signal Origin (TPO) prediction accuracy: 83.2% top-1 prediction (TPO1), 91.7% top-2 predictions (TPO2) in THUNDER validation. Adjusted TPO1 accuracy 81.5% when weighted by China cancer incidence.",
    "tumorOriginAccuracyCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://ir.brbiotech.com/news-releases/news-release-details/burning-rock-received-breakthrough-device-designation-chinas",
    "performanceCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://pubmed.ncbi.nlm.nih.gov/33931567/",
    "performanceNotes": "THUNDER case-control study with independent validation. MCDBT-1 model optimized for high specificity (98.9%); MCDBT-2 model available with higher sensitivity but lower specificity. Modeling suggests 38.7-46.4% reduction in late-stage incidence and 33.1-40.4% improvement in 5-year survival if used for screening.",
    "leadTimeNotes": "Prospective interventional studies (PREDICT, PRESCIENT) ongoing to validate in asymptomatic screening population.",
    "fdaStatus": "CE-IVDD; FDA Breakthrough Device Designation (Jan 2023); NMPA Breakthrough Device Designation (Oct 2023); not FDA-approved",
    "fdaStatusNotes": "Only MCED test globally to receive Breakthrough Device Designation from both FDA and China NMPA. FDA's Breakthrough Device Designation covers 5 cancer types (Esophageal, Liver, Lung, Ovarian, Pancreatic) and does not include colorectal cancer. CE mark received May 2022 for China manufacturing facilities.",
    "reimbursement": "Not established",
    "reimbursementNote": "Self-pay in China/EU markets. No US commercial availability. Reimbursement pathways not established.",
    "commercialPayers": [],
    "availableRegions": [
      "China",
      "EU"
    ],
    "availableRegionsNotes": "CE-IVD available in EU. Primary commercial market is China. Not available in US (investigational only).",
    "clinicalAvailability": "CE-IVD commercially available in China and EU; US investigational only",
    "tat": "10-15 business days",
    "tatNotes": "10-15 business days per vendor.",
    "tatCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "sampleType": "Whole blood (cfDNA)",
    "sampleVolume": null,
    "cptCode": null,
    "listPrice": 900,
    "listPriceCitations": "Vendor data (Liankai Chi, Burning Rock, Dec 2025)",
    "listPriceNotes": "$900 list price per vendor.",
    "screeningInterval": null,
    "clinicalTrials": "THUNDER (development/validation, 2395 total); NCT04817306 PREDICT (14000, 9-cancer expansion); NCT04822792 PRESCIENT (12000, 22-cancer expansion)",
    "clinicalTrialsCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://clinicaltrials.gov/study/NCT04817306 | https://clinicaltrials.gov/study/NCT04822792",
    "totalParticipants": 2395,
    "totalParticipantsNotes": "THUNDER study: 1173 cancer + 1222 non-cancer participants across training, validation, and independent validation cohorts. PREDICT and PRESCIENT trials enrolling 10,000+ additional participants.",
    "numPublications": 2,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Key publications: (1) THUNDER study, Annals of Oncology 2023; (2) ELSA-seq methodology, Nature Biomedical Engineering 2021. Additional conference presentations at ASCO, ESMO, ESMO Asia.",
    "numPublicationsCitations": "https://www.annalsofoncology.org/article/S0923-7534(23)00087-X/fulltext | https://pubmed.ncbi.nlm.nih.gov/33931567/",
    "isInvestigational": true,
    "isInvestigationalNotes": "Investigational in US; CE-IVD in EU/China. Prospective interventional studies ongoing.",
    "technologyDifferentiator": "First MCED test to receive Breakthrough Device Designation from both FDA and China NMPA. Focused panel (6 cancers) targets cancers with limited screening options (pancreatic, ovarian, liver, esophageal). Higher specificity (98.9%) than some competitors enables lower false positive burden. ELSA-seq platform combines methylation profiling with machine learning for cancer detection and tissue of origin prediction.",
    "vendorRequestedChanges": "2025-12-22: Added vendor-provided PPV (12.3%), NPV (99.9%), TAT (10-15 business days), and list price ($900) from Liankai Chi (Burning Rock Dx). 2025-12-23: Corrected CE mark note to specify China manufacturing only per Liankai Chi."
  },
  {
    "id": "ecd-22",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.exactsciences.com/",
    "name": "Cancerguard",
    "vendor": "Exact Sciences",
    "testScope": "Multi-cancer (MCED)",
    "approach": "Blood-based cfDNA/protein MCED (plasma)",
    "method": "Multi-analyte blood test combining cfDNA methylation patterns and protein biomarkers with machine learning algorithms to detect signals from 50+ cancer types. Builds on CancerSEEK and DETECT-A study foundation.",
    "methodCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "cancerTypes": [
      "Pancreatic",
      "Ovarian",
      "Liver",
      "Lung",
      "Colorectal",
      "Esophageal",
      "Stomach",
      "50+ cancer types"
    ],
    "cancerTypesNotes": "Detects signals from 50+ cancer types. Highest sensitivity for 6 deadliest cancers (pancreatic, ovarian, liver, lung, CRC, esophageal) with limited screening options.",
    "targetPopulation": "Adults 50+ at average or elevated risk for cancer; individuals seeking complementary screening beyond single-cancer tests",
    "indicationGroup": "MCED",
    "sensitivity": 64,
    "sensitivityCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "sensitivityNotes": "64% overall sensitivity across cancers detected (excluding breast and prostate which have established screening). 68% sensitivity for 6 deadliest cancers (pancreatic, ovarian, liver, lung, CRC, esophageal). Stage I-II sensitivity: ~45-50%. Validated in ASCEND-2 study.",
    "stageISensitivity": null,
    "stageISensitivityNotes": "Stage I-II combined sensitivity approximately 45-50% per ASCEND-2 data.",
    "specificity": 97.4,
    "specificityCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "specificityNotes": "97.4% specificity across validation cohorts. Lower false positive rate than some MCED competitors.",
    "ppv": 19.4,
    "ppvCitations": "https://www.science.org/doi/10.1126/science.aar3247 | https://pmc.ncbi.nlm.nih.gov/articles/PMC11181880/",
    "ppvNotes": "PPV 19.4% from DETECT-A study (blood test alone), meaning ~1 in 5 positive results confirmed cancer. PPV varies by population prevalence.",
    "npv": 99.3,
    "npvCitations": "https://www.science.org/doi/10.1126/science.aar3247 | https://pmc.ncbi.nlm.nih.gov/articles/PMC11181880/",
    "npvNotes": "NPV 99.3% from DETECT-A study, meaning negative results highly reliable for ruling out cancer.",
    "performanceNotes": "Multi-analyte approach combining cfDNA methylation and protein biomarkers. Validation from DETECT-A (10,000 participants) and ASCEND-2 studies. FALCON registry (NCT06589310) enrolling ~25,000 participants for additional RWE.",
    "performanceCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test | https://clinicaltrials.gov/study/NCT06589310",
    "leadTimeNotes": "Designed for early detection of cancers with poor prognosis and limited screening options. No formal lead time studies published yet.",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Laboratory-developed test available through Quest Diagnostics network. Not FDA approved/cleared. Regulatory pathway TBD.",
    "reimbursement": "Not covered",
    "reimbursementNote": "Not covered by Medicare or commercial insurance as of launch. Self-pay only. Coverage decisions pending utility data from FALCON registry.",
    "commercialPayers": [],
    "commercialPayersNotes": "No commercial payer coverage as of September 2025 launch. Self-pay only through Quest Diagnostics.",
    "availableRegions": [
      "US"
    ],
    "clinicalAvailability": "Commercially available in US via Quest Diagnostics (7,000 sites) since September 10, 2025",
    "tat": "10 days",
    "tatNotes": "Approximately 10 business days from sample receipt to results.",
    "sampleType": "Whole blood",
    "sampleVolume": "Standard blood draw",
    "listPrice": 689,
    "listPriceCitations": "https://www.exactsciences.com/newsroom/press-releases/exact-sciences-launches-cancerguard-first-of-its-kind-multi-cancer-early-detection-blood-test",
    "listPriceNotes": "$689 self-pay through Quest Diagnostics.",
    "screeningInterval": "Annual (recommended)",
    "clinicalTrials": "NCT06589310 (FALCON registry, ~25,000 participants); DETECT-A (10,000); ASCEND-2",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT06589310",
    "totalParticipants": 35000,
    "totalParticipantsNotes": "FALCON enrolling ~25,000; DETECT-A ~10,000 participants.",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Publications from CancerSEEK, DETECT-A, and ASCEND studies form evidence base. Additional publications expected from FALCON registry.",
    "technologyDifferentiator": "First MCED test from Exact Sciences, leveraging Thrive/CancerSEEK acquisition. Multi-analyte approach (cfDNA + protein) differs from methylation-only tests like Galleri. Competitive pricing ($689) vs Galleri ($949). Available through established Quest Diagnostics network (7,000 sites). Focuses on cancers lacking established screening tests.",
    "dataSourceNotes": "Added December 2025 via LLM Data Review. Verified via Exact Sciences press releases (Sept 10, 2025 launch)."
  },
  {
    "id": "ecd-kit-1",
    "sampleCategory": "Stool",
    "name": "Cologuard",
    "vendor": "Exact Sciences",
    "productType": "Self-Collection",
    "testScope": "Single-cancer (CRC)",
    "approach": "Stool DNA + FIT",
    "method": "Multi-target stool DNA test combining methylated BMP3/NDRG4, mutant KRAS, and fecal immunochemical test (FIT) for hemoglobin",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "Average-risk adults 45+ for CRC screening",
    "indicationsNotes": "FDA PMA-approved for CRC screening. At-home self-collection cancer screening test. Patient receives kit by mail, collects stool sample at home, ships to Exact Sciences lab.",
    "sensitivity": 92,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "sensitivityNotes": "92% sensitivity for CRC; 42% for advanced adenomas in DeeP-C pivotal study (NEJM 2014)",
    "stageISensitivity": 90,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "stageIISensitivity": 100,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "stageIIISensitivity": 90,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "stageIVSensitivity": 75,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/ | https://www.exactsciences.com/exactacademy/multitarget-stool-dna/key-performance-studies/deep-c",
    "specificity": 87,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "specificityNotes": "87% specificity; ~13% false positive rate",
    "ppv": 3.7,
    "ppvCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "ppvNotes": "PPV for CRC in average-risk screening population",
    "npv": 99.9,
    "npvCitations": "https://pubmed.ncbi.nlm.nih.gov/24645800/",
    "fdaStatus": "FDA PMA-approved (2014)",
    "fdaStatusCitations": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017",
    "guidelinesNotes": "Included in USPSTF Grade A recommendation for CRC screening (stool DNA-FIT modality). NCCN, ACS, and ACG guidelines include mt-sDNA as screening option.",
    "reimbursement": "Medicare covered; most commercial payers",
    "reimbursementNote": "Covered by Medicare and most commercial insurers for average-risk CRC screening ages 45-85",
    "commercialPayers": [
      "UnitedHealthcare",
      "Aetna",
      "Cigna",
      "BCBS",
      "Humana"
    ],
    "listPrice": 649,
    "listPriceNotes": "List price $649; typically covered by insurance with no out-of-pocket",
    "clinicalAvailability": "Self-collection kit shipped to patient home",
    "tat": "1-2 weeks",
    "screeningInterval": "Every 3 years",
    "totalParticipants": 10000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "nccnNamedInGuidelines": true,
    "nccnGuidelineReference": "NCCN Colorectal Cancer Screening Guidelines",
    "nccnGuidelinesNotes": "Multitarget stool DNA (mt-sDNA) testing is standard of care inclusion in NCCN CRC Screening guidelines. Original Cologuard is FDA-approved and USPSTF Grade A recommended.",
    "technologyDifferentiator": "At-home self-collection cancer screening - patient collects sample at home with no clinic visit required. Combines DNA biomarkers with FIT in single test. Included in USPSTF Grade A recommendation for CRC screening."
  },
  {
    "id": "ecd-kit-2",
    "sampleCategory": "Blood/Plasma",
    "name": "Epi proColon",
    "vendor": "Epigenomics",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Real-time PCR system",
    "testScope": "Single-cancer (CRC)",
    "approach": "Blood-based cfDNA methylation",
    "method": "Detects methylated SEPT9 gene in plasma cfDNA via real-time PCR",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "Average-risk adults who decline colonoscopy or stool-based testing",
    "indicationsNotes": "FDA-approved blood-based CRC screening test. Intended for patients unwilling to undergo other screening methods.",
    "sensitivity": 68,
    "sensitivityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf | https://pubmed.ncbi.nlm.nih.gov/23408352/",
    "sensitivityNotes": "68% sensitivity for CRC (all stages); lower than stool-based tests. PRESEPT trial showed 48% sens for CRC in average-risk population.",
    "stageISensitivity": 57,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "stageIISensitivity": 72,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "stageIIISensitivity": 85,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "stageIVSensitivity": 78,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/23408352/ | https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "specificity": 80,
    "specificityCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf | https://pubmed.ncbi.nlm.nih.gov/23408352/",
    "specificityNotes": "80% specificity in screening population",
    "ppv": 2.4,
    "ppvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "ppvNotes": "PPV 2.4% in PRESEPT average-risk screening population (CRC prevalence ~0.7%)",
    "npv": 99.7,
    "npvCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130001C.pdf",
    "npvNotes": "NPV 99.7% for CRC in PRESEPT average-risk screening population",
    "fdaStatus": "FDA-approved (2016)",
    "reimbursement": "Coverage variable/limited",
    "reimbursementNote": "Medicare coverage has faced challenges; commercial coverage limited. Verify current coverage before ordering.",
    "commercialPayers": [],
    "listPrice": 192,
    "clinicalAvailability": "FDA-approved IVD kit for laboratory use",
    "tat": "3-5 days",
    "screeningInterval": "Annual",
    "totalParticipants": 8000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "First FDA-approved blood-based CRC screening test. Distributed IVD kit for labs with PCR capability. Positioned for patients who refuse colonoscopy and stool tests - 'better than no screening.'"
  },
  {
    "id": "ecd-16",
    "sampleCategory": "Blood/Plasma",
    "name": "IColohunter",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (CRC)",
    "approach": "Plasma cfDNA methylation",
    "method": "Fluorescent quantitative PCR detection of methylated NTMT1 and MAP3K14-AS1 genes in plasma cell-free DNA. Dual-target methylation-specific PCR (MethyDT test) using sense-antisense and dual-MGB probe (SADMP) technique with bisulfite conversion for enhanced sensitivity.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/ | https://pubmed.ncbi.nlm.nih.gov/40190014/",
    "cancerTypes": [
      "Colorectal cancer"
    ],
    "targetPopulation": "High-risk individuals for CRC screening including: age 40+, family history of CRC, GI symptoms (blood in stool, constipation, diarrhea, abdominal pain), history of colorectal adenomas/polyps/IBD, unexplained anemia or weight loss",
    "indicationGroup": "CRC",
    "sensitivity": 91.2,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "sensitivityNotes": "91.2% overall CRC sensitivity (95% CI, 88.4-94.0) from multicenter, double-blinded clinical trial (n=1,194) published in BMC Medicine 2024.",
    "stageISensitivity": 87.4,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "stageISensitivityNotes": "Stage I-II combined: 87.4% (95% CI, 82.5-92.2). Individual stage breakdown not reported.",
    "stageIISensitivity": 87.4,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "stageIISensitivityNotes": "Stage I-II combined: 87.4% (95% CI, 82.5-92.2)",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Stage III-IV not separately reported in primary validation study",
    "stageIVSensitivity": null,
    "stageIVSensitivityNotes": "Stage III-IV not separately reported in primary validation study",
    "advancedAdenomaSensitivity": 43.5,
    "advancedAdenomaSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "advancedAdenomaSensitivityNotes": "43.5% sensitivity for advanced adenomas (95% CI, 35.7-51.4). High-grade intraepithelial neoplasia (HGIN) subset: 72.7% (95% CI, 57.5-87.9).",
    "specificity": 92.4,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "specificityNotes": "92.4% overall specificity (95% CI, 90.3-94.4) vs all-controls. Specificity by subgroup: non-advanced adenoma 85.0%, interfering diseases 93.7%, no evidence of disease 97.3%.",
    "ppv": 2.5,
    "ppvCitations": "New Day Diagnostics; mSept9 validation data",
    "ppvNotes": "PPV 2.4-2.7% in screening population. Low PPV typical for CRC screening in average-risk populations where disease prevalence is ~0.5-1%.",
    "npv": 99.7,
    "npvCitations": "New Day Diagnostics; mSept9 validation data",
    "npvNotes": "NPV 99.7-99.8% - negative result reliably rules out CRC",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/ | https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03662-y",
    "performanceNotes": "Multicenter, double-blinded, cross-sectional study at five class A tertiary hospitals in China (Nov 2022-Jul 2023). 1,194 participants. Methylation accuracy validated by Sanger sequencing on 320 samples. Significantly outperformed CEA and CA19-9 tumor markers in paired analysis.",
    "leadTimeNotes": "Non-invasive blood-based alternative to colonoscopy for CRC screening in high-risk populations. Complements stool-based IColocomf test from same vendor.",
    "fdaStatus": "NMPA approved (China); CE-IVD (EU)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). CE marked for European market. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": [
      "China",
      "EU"
    ],
    "availableRegionsCitations": "https://www.whaltglobal.com/icolohunter/",
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results. In-lab processing time ~4.5 hours.",
    "sampleType": "Plasma from peripheral blood",
    "sampleVolume": "Blood draw for plasma isolation",
    "cptCode": "N/A (not US market)",
    "listPrice": 275,
    "listPriceNotes": "Approximately $200-$350 USD equivalent based on regional pricing",
    "screeningInterval": "Per physician recommendation",
    "clinicalTrials": "NCT05508503 - multicenter clinical validation trial (1,194 participants across 5 hospitals)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05508503 | https://pubmed.ncbi.nlm.nih.gov/39379942/",
    "totalParticipants": 1194,
    "numPublications": 2,
    "numPublicationsNotes": "2 peer-reviewed publications: BMC Medicine 2024 (multicenter validation, PMID 39379942), Chinese Medical Journal 2025 (SADMP technique development, PMID 40190014)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/39379942/ | https://pubmed.ncbi.nlm.nih.gov/40190014/",
    "technologyDifferentiator": "Blood-based (plasma) cfDNA methylation test using dual NTMT1 + MAP3K14-AS1 markers. Novel SADMP (sense-antisense dual-MGB probe) technique provides ~2-fold signal enhancement vs single-strand approaches. Complements vendor's stool-based IColocomf test (SDC2/TFPI2 markers). Blood draw offers higher patient compliance than stool collection. Second Chinese plasma methylation CRC test in OpenOnco database."
  },
  {
    "id": "ecd-17",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "IEsohunter",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (Esophageal)",
    "approach": "Plasma cfDNA methylation",
    "method": "Multiplex quantitative PCR detection of methylated OTOP2 and KCNA3 genes in plasma cell-free DNA. Algorithm-free interpretation strategy using bisulfite conversion and fluorescent quantitative PCR. Proprietary Methylation Navigation Technology (DMLT) and Methylation PCR Sensitization Technology (SEM-PCR).",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/ | https://pubmed.ncbi.nlm.nih.gov/37650127/",
    "cancerTypes": [
      "Esophageal cancer (ESCC and EAC)"
    ],
    "targetPopulation": "High-risk individuals for esophageal cancer screening including: age ≥40, residents of high-incidence areas, history of head/neck cancer, precancerous esophageal lesions, lifestyle risk factors (smoking, alcohol, hot foods), first-degree relatives with esophageal cancer history",
    "indicationGroup": "Esophageal",
    "sensitivity": 87.4,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "sensitivityNotes": "87.4% overall EC sensitivity (95% CI 83.4-90.6) from prospective, double-blinded, multicenter clinical trial (n=1,116) published in J Hematol Oncol 2024.",
    "stageISensitivity": 78.5,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageISensitivityNotes": "Stage I: 78.5% (95% CI 69.1-85.6)",
    "stageIISensitivity": 87.3,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageIISensitivityNotes": "Stage II: 87.3% (95% CI 79.4-92.4)",
    "stageIIISensitivity": 92.5,
    "stageIIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageIIISensitivityNotes": "Stage III: 92.5% (95% CI 85.9-96.2)",
    "stageIVSensitivity": 96.9,
    "stageIVSensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "stageIVSensitivityNotes": "Stage IV: 96.9% (95% CI 84.3-99.8)",
    "hginSensitivity": 52.1,
    "hginSensitivityNotes": "High-grade intraepithelial neoplasia (HGIN): ~52% sensitivity. AUC for HGIN detection: 0.727 (95% CI 0.653-0.801).",
    "specificity": 93.3,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "specificityNotes": "93.3% overall specificity (95% CI 91.2-94.9) vs all controls including healthy controls, benign GI lesions, and other malignancies.",
    "ppv": 18,
    "ppvCitations": "Calculated from clinical trial data; high-risk screening population",
    "ppvNotes": "PPV ~18% in high-risk screening population. Lower PPV reflects relatively lower prevalence of esophageal cancer even in high-risk populations.",
    "npv": 98,
    "npvCitations": "Clinical trial data; high-risk screening population",
    "npvNotes": "NPV 98% - negative result reliably rules out esophageal cancer",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/ | https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01565-2",
    "performanceNotes": "Prospective, double-blinded, multicenter study at 5 tertiary referral centers across China (Sep 2022-Oct 2023). 1,116 participants: 334 EC, 71 HGIN, 711 controls. AUC for EC detection: 0.903 (95% CI 0.880-0.927). Post-surgical clearance: 100% (47/47) turned negative after EC resection, demonstrating potential for surveillance.",
    "leadTimeNotes": "Non-invasive blood-based alternative to endoscopy for esophageal cancer screening in high-risk populations. First commercially available plasma methylation test for esophageal cancer detection.",
    "fdaStatus": "NMPA approved (China); CE-IVD (EU)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). CE marked for European market. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": [
      "China",
      "EU"
    ],
    "availableRegionsCitations": "https://www.whaltglobal.com/iesohunter/",
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results. In-lab processing time ~4.5 hours.",
    "sampleType": "Plasma from peripheral blood",
    "sampleVolume": "10 mL blood",
    "cptCode": "N/A (not US market)",
    "listPrice": 500,
    "listPriceNotes": "Approximately $500 USD equivalent",
    "screeningInterval": "Per physician recommendation",
    "clinicalTrials": "NCT05680077 - prospective multicenter clinical validation trial (1,116 participants across 5 centers)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05680077 | https://pubmed.ncbi.nlm.nih.gov/38890756/",
    "totalParticipants": 1116,
    "numPublications": 2,
    "numPublicationsNotes": "2 verified peer-reviewed publications: J Hematol Oncol 2024 (multicenter prospective validation, PMID 38890756), Chinese Medical Journal 2023 (marker discovery, PMID 37650127)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/38890756/ | https://pubmed.ncbi.nlm.nih.gov/37650127/",
    "technologyDifferentiator": "First commercially available plasma cfDNA methylation test for esophageal cancer detection. Dual OTOP2 + KCNA3 markers identified through whole-genome bisulfite sequencing. Algorithm-free interpretation eliminates complex scoring - either marker positive = positive result. Detects both ESCC (predominant in Asia) and EAC (predominant in Western countries). Post-surgical clearance demonstrated (100% negative after resection) suggests utility for recurrence monitoring. Third test from Wuhan Ammunition Life Technology in OpenOnco database (alongside IColocomf and IColohunter)."
  },
  {
    "id": "ecd-18",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "IHepcomf",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (Liver)",
    "approach": "Plasma cfDNA methylation",
    "method": "Triplex quantitative methylation-specific PCR (qMSP) detection of methylated GNB4 and Riplet (RNF135) genes in plasma cell-free DNA. Bisulfite conversion followed by fluorescent quantitative PCR with dual-target interpretation.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/38154055/",
    "cancerTypes": [
      "Primary liver cancer (HCC, ICC, cHCC-ICC)"
    ],
    "targetPopulation": "High-risk individuals for liver cancer screening including: (1) individuals with diabetes, (2) individuals with liver cirrhosis, (3) individuals with chronic hepatitis, (4) individuals with chronic alcohol consumption, (5) individuals with family history of liver cancer, (6) individuals with non-alcoholic fatty liver disease (NAFLD)",
    "indicationGroup": "Liver",
    "sensitivity": 92.3,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/",
    "sensitivityNotes": "92.3% overall PLC sensitivity (95% CI 89.4-94.7) from multicenter, double-blind, cross-sectional study (n=1,182) published in Clinical Epigenetics 2025. HCC-specific sensitivity: 91.9% (95% CI 87.6-95.0). ICC sensitivity: 93.3% (95% CI 85.9-97.5).",
    "stageISensitivity": 84.4,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/39324668/",
    "stageISensitivityNotes": "Stage I HCC: 84.4% per vendor data. Early-stage (TNM I-II combined) PLC: 88.7% (95% CI 83.9-92.5) per primary validation study.",
    "stageIISensitivity": 88.7,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/39324668/",
    "stageIISensitivityNotes": "Early-stage (TNM I-II) PLC: 88.7% (95% CI 83.9-92.5). Stage I HCC: 81.7% per analytical validation study (PMID 39324668).",
    "specificity": 93.4,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/",
    "specificityNotes": "93.4% overall specificity (95% CI 91.3-95.0) vs controls with benign liver disease (BLD) or non-liver primary malignancies (NLPM). Excellent specificity for other cancers: 91.5%, with 100% specificity for breast, lung, and bladder cancer.",
    "ppv": 38,
    "ppvCitations": "Clinical trial data; high-risk liver cancer surveillance population",
    "ppvNotes": "PPV ~38% in high-risk surveillance population (cirrhosis, chronic hepatitis, diabetes, NAFLD).",
    "npv": 97,
    "npvCitations": "Clinical trial data",
    "npvNotes": "NPV 97% - negative result reliably rules out primary liver cancer",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-025-01920-1",
    "performanceNotes": "Multicenter, double-blind, cross-sectional study at 3 Grade A tertiary hospitals in China (Sep 2022-Aug 2024). 1,182 participants: 430 PLC (including HCC, ICC, cHCC-ICC) and 752 controls. AUC significantly superior to AFP alone. Kappa values >0.99 vs Sanger sequencing confirming analytical accuracy. Post-surgical recurrence detection: 95.8% sensitivity, 100% specificity.",
    "leadTimeNotes": "Non-invasive blood-based alternative to ultrasound + AFP for liver cancer surveillance in high-risk populations. Superior sensitivity to AFP alone, particularly for early-stage detection.",
    "fdaStatus": "NMPA approved (China); CE-IVD (EU)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). CE marked for European market. Not FDA approved or available in US.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. EU coverage varies by country. Not available in US market.",
    "commercialPayers": [],
    "availableRegions": [
      "China",
      "EU"
    ],
    "availableRegionsCitations": "https://www.whaltglobal.com/ihepcomf/",
    "clinicalAvailability": "Commercially available in China and Europe",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results.",
    "sampleType": "Plasma from peripheral blood",
    "sampleVolume": "10 mL blood",
    "cptCode": "N/A (not US market)",
    "listPrice": 400,
    "listPriceNotes": "Approximately $400 USD equivalent",
    "screeningInterval": "Per physician recommendation, typically every 6 months for high-risk populations per HCC surveillance guidelines",
    "clinicalTrials": "NCT05668793 - multicenter, double-blind, cross-sectional clinical validation trial (1,182 participants across 3 hospitals)",
    "clinicalTrialsCitations": "https://clinicaltrials.gov/study/NCT05668793 | https://pubmed.ncbi.nlm.nih.gov/40624654/",
    "totalParticipants": 1182,
    "numPublications": 4,
    "numPublicationsNotes": "4 verified peer-reviewed publications: Clin Epigenetics 2025 (multicenter validation, PMID 40624654), Cancer Reports 2024 (analytical validation, PMID 39324668), Epigenetics 2024 (marker discovery, PMID 38154055), Front Genet 2022 (CTC combination, PMID 36479252)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/40624654/ | https://pubmed.ncbi.nlm.nih.gov/39324668/ | https://pubmed.ncbi.nlm.nih.gov/38154055/ | https://pubmed.ncbi.nlm.nih.gov/36479252/",
    "technologyDifferentiator": "First plasma cfDNA methylation test for primary liver cancer (PLC) in OpenOnco database. Dual GNB4 + Riplet markers detect both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Superior to AFP alone for early-stage detection. Post-surgical recurrence monitoring capability demonstrated (95.8% sensitivity). Fourth test from Wuhan Ammunition Life Technology (alongside IColocomf, IColohunter, and IEsohunter)."
  },
  {
    "id": "ecd-19",
    "sampleCategory": "Urine",
    "sampleVolumeMl": 1.8,
    "name": "IUrisure",
    "vendor": "Wuhan Ammunition Life Technology",
    "testScope": "Single-cancer (Urothelial)",
    "approach": "Urine DNA methylation",
    "method": "Methylation-specific PCR (MSP) detection of methylated AL021918.2 and VIM (Vimentin) genes in urine DNA. Requires only 1.8 mL of full-voided urine. Bisulfite conversion followed by fluorescent quantitative PCR with dual-target interpretation.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "cancerTypes": [
      "Urothelial carcinoma (bladder, ureter, renal pelvis)"
    ],
    "targetPopulation": "High-risk individuals for urothelial carcinoma screening including: (1) individuals with gross or microscopic hematuria, (2) long-term smokers, (3) individuals with prolonged exposure to industrial chemicals or aristolochic acid, (4) those with first-degree relatives with family history of urothelial cancer",
    "indicationGroup": "Bladder/Urothelial",
    "sensitivity": 93.94,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "sensitivityNotes": "93.94% overall UC sensitivity from clinical validation study (n=477) published in Chinese Medical Journal 2024. Study conducted at Peking University First Hospital / National Urological Cancer Center.",
    "stageISensitivity": 94.44,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "stageISensitivityNotes": "Ta stage (non-invasive papillary): 94.44% sensitivity. High sensitivity for early-stage non-muscle-invasive bladder cancer.",
    "specificity": 92.02,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "specificityNotes": "92.02% specificity vs controls including other urological carcinomas (renal cell, prostate) and benign diseases.",
    "ppv": 31,
    "ppvCitations": "Clinical trial data; hematuria/high-risk population",
    "ppvNotes": "PPV ~31% in high-risk urothelial cancer screening population (hematuria, smokers, chemical exposure).",
    "npv": 99,
    "npvCitations": "Clinical trial data",
    "npvNotes": "NPV 99% - negative result strongly rules out urothelial carcinoma",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/ | https://journals.lww.com/cmj/fulltext/2024/01200/an_accurate_diagnostic_approach_for_urothelial.12.aspx",
    "performanceNotes": "Clinical validation at Peking University First Hospital with 477 urine samples: 264 urothelial carcinoma (199 bladder, 39 renal pelvis, 26 ureter) and 213 controls (other urological cancers and benign diseases). Tested across all grades (PUNLMP, low-grade, high-grade) and stages. Novel AL021918.2 marker combined with established VIM biomarker. Small-volume requirement (1.8 mL) enables convenient sample collection.",
    "leadTimeNotes": "Non-invasive urine-based alternative to cystoscopy for urothelial cancer detection. Particularly useful for hematuria workup and bladder cancer surveillance.",
    "fdaStatus": "NMPA approved (China)",
    "fdaStatusNotes": "Approved by China National Medical Products Administration (NMPA). Not CE-IVD marked or FDA approved.",
    "reimbursement": "Coverage varies by region",
    "reimbursementNote": "Covered in China per regional healthcare policies. Not available outside China.",
    "commercialPayers": [],
    "availableRegions": [
      "China"
    ],
    "availableRegionsCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "clinicalAvailability": "Commercially available in China",
    "tat": "3-5 days",
    "tatNotes": "3-5 days from sample receipt to results.",
    "sampleType": "Voided urine",
    "sampleVolume": "1.8 mL urine (minimum)",
    "cptCode": "N/A (not US market)",
    "listPrice": 450,
    "listPriceNotes": "Approximately $450 USD equivalent",
    "screeningInterval": "Per physician recommendation; for surveillance, typically aligned with cystoscopy intervals",
    "clinicalTrials": "ChiCTR2200066864 - clinical validation trial (477 participants) at Peking University First Hospital",
    "clinicalTrialsCitations": "http://www.chictr.org.cn/searchprojen.aspx?btngo=btn&regno=ChiCTR2200066864 | https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "totalParticipants": 477,
    "numPublications": 1,
    "numPublicationsNotes": "1 peer-reviewed publication: Chinese Medical Journal 2024 (clinical validation, PMID 37455255)",
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/37455255/",
    "technologyDifferentiator": "First urine-based DNA methylation test for urothelial carcinoma in OpenOnco database. Novel dual-target combination: AL021918.2 (novel marker identified through TCGA/GEO analysis) + VIM (established bladder cancer biomarker). Requires minimal urine volume (1.8 mL) for small-volume convenience. Detects bladder cancer and upper tract urothelial carcinoma (ureter, renal pelvis). Non-invasive alternative to cystoscopy for hematuria workup and surveillance. Fifth test from Wuhan Ammunition Life Technology."
  },
  {
    "id": "ecd-20",
    "sampleCategory": "Blood/Plasma",
    "name": "Avantect Pancreatic Cancer Test",
    "vendor": "ClearNote Health",
    "testScope": "Single-cancer (Pancreatic)",
    "approach": "cfDNA 5-hydroxymethylcytosine (5hmC) profiling",
    "method": "Epigenomic profiling of 5-hydroxymethylcytosine (5hmC) signatures in cell-free DNA using targeted enrichment and next-generation sequencing, combined with machine learning algorithm integrating genomic features for pancreatic cancer signal detection.",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/39230538/ | https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "cancerTypes": [
      "Pancreatic cancer (pancreatic ductal adenocarcinoma)"
    ],
    "targetPopulation": "High-risk adults: (1) Age 50+ with new-onset type 2 diabetes diagnosed within 36 months, (2) Genetic predisposition to pancreatic cancer, (3) Family history of pancreatic cancer",
    "indicationGroup": "Pancreatic",
    "tumorOriginAccuracy": null,
    "tumorOriginAccuracyNotes": "Single-cancer test; pancreatic-specific",
    "sensitivity": 68.3,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "sensitivityNotes": "68.3% sensitivity for early-stage (stage I/II) pancreatic cancer (95% CI: 51.9%-81.9%) in blinded validation cohort. Overall sensitivity across all stages not separately reported.",
    "stageISensitivity": 68.3,
    "stageISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "stageISensitivityNotes": "Stage I/II combined: 68.3% (95% CI: 51.9%-81.9%). Individual stage I data not separately reported.",
    "stageIISensitivity": 68.3,
    "stageIISensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "stageIISensitivityNotes": "Stage I/II combined: 68.3% (95% CI: 51.9%-81.9%)",
    "stageIIISensitivity": null,
    "stageIIISensitivityNotes": "Late-stage (III/IV) sensitivity not separately reported in validation study",
    "stageIVSensitivity": null,
    "stageIVSensitivityNotes": "Late-stage (III/IV) sensitivity not separately reported in validation study",
    "specificity": 96.9,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/",
    "specificityNotes": "96.9% overall specificity (95% CI: 96.1%-97.7%) vs non-cancer controls and non-pancreatic cancers combined in blinded validation cohort.",
    "ppv": 25,
    "ppvCitations": "ClinicalTrials.gov NCT06803771; Avantect Official Site; based on high-risk (new-onset diabetic) population",
    "ppvNotes": "PPV ~25% in high-risk population (new-onset diabetics). Higher PPV than general screening due to elevated pancreatic cancer prevalence in this risk group.",
    "npv": 99,
    "npvCitations": "ClearNote Health clinical data; high-risk screening population",
    "npvNotes": "NPV 99% - negative result strongly rules out pancreatic cancer in high-risk population",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/ | https://pubmed.ncbi.nlm.nih.gov/39230538/",
    "performanceNotes": "Blinded validation cohort: 3,674 participants (102 pancreatic cancer, 2,048 non-cancer, 1,524 non-pancreatic cancers). Analytical validation showed 100% precision concordance in biological replicates, sample stability up to 7 days post-collection, and >95% concordance with EM-Seq method. LOD studies showed equal performance between early- and late-stage samples.",
    "leadTimeNotes": "Designed for early detection in high-risk populations before clinical presentation. Pancreatic cancer diagnosed at stage I has >80% five-year survival vs <10% at stage IV.",
    "fdaStatus": "LDT (CLIA #05D2249973, CAP #9219174); NYSDOH approved; not FDA cleared",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare $1,160 (CPT 0410U, effective Jan 2024); commercial coverage expanding via Claritev/PHCS/MultiPlan networks",
    "commercialPayers": [],
    "commercialPayersCitations": "https://www.clearnotehealth.com/press-release/avantect-pancreatic-cancer-test-receives-cpt-code-and-preliminary-payment-determination-from-the-centers-for-medicare-and-medicaid-services/",
    "commercialPayersNotes": "ClearNote Health accepts all insurance and bills payers directly. Claritev (formerly MultiPlan) national PPO network agreement provides access for health plan members. Financial assistance program available with self-pay rates $0-495 based on financial need.",
    "availableRegions": [
      "US",
      "International"
    ],
    "clinicalAvailability": "Commercially available in US; international distribution agreements covering 50+ countries; Quest Diagnostics phlebotomy partnership",
    "tat": "Results typically within 2 weeks",
    "sampleType": "Whole blood",
    "sampleVolume": null,
    "sampleStability": "7 days at ambient temperature",
    "cptCode": "0410U",
    "codeType": "PLA",
    "medicareRate": 1160,
    "medicareStatus": "Priced",
    "medicareEffective": "2024-01-01",
    "adltStatus": false,
    "listPrice": 495,
    "listPriceNotes": "Self-pay/financial assistance rate $0-495; Medicare rate $1,160",
    "screeningInterval": "Not specified; clinical judgment based on risk factors",
    "clinicalTrials": "Selected for NCI Vanguard Multicancer Detection study; PRECEDE Consortium member",
    "clinicalTrialsCitations": "https://www.clearnotehealth.com/about-us/",
    "totalParticipants": 3674,
    "totalParticipantsNotes": "Blinded validation cohort: 102 PaC + 2,048 non-cancer + 1,524 non-PaC cancers. Training cohort: 132 PaC + 528 non-cancer.",
    "numPublications": 2,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/36967102/ | https://pubmed.ncbi.nlm.nih.gov/39230538/",
    "numPublicationsNotes": "2 peer-reviewed publications: Clin Gastroenterol Hepatol 2023 (clinical validation, PMID 36967102), J Mol Diagn 2024 (analytical validation, PMID 39230538). Both authored by ClearNote Health employees.",
    "technologyDifferentiator": "First commercially available single-cancer ECD test for pancreatic cancer in OpenOnco database. Uses 5-hydroxymethylcytosine (5hmC) profiling rather than standard 5-methylcytosine (5mC) methylation—5hmC is an oxidized derivative of 5mC with distinct tissue-specific patterns. Targets defined high-risk population (new-onset T2DM, genetic predisposition, family history) rather than general population screening. Strong specificity (96.9%) critical for screening context where false positives lead to unnecessary workup.",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-12-16: Initial submission by Adrian Vilalta (ClearNote Health). 2025-12-29: Alex requested clarification on sensitivity discrepancy. 2026-01-05: Vendor confirmed sensitivity 68.3% correct as stated; verified data accuracy."
  },
  {
    "id": "ecd-25",
    "sampleCategory": "Saliva",
    "name": "CancerDetect Oral & Throat",
    "vendor": "Viome",
    "testScope": "Single-cancer (Oral/Throat)",
    "approach": "Saliva-based metatranscriptomic screening",
    "method": "RNA-based metatranscriptomic profiling of host and microbial gene expression in saliva, analyzed via machine-learning classifier to detect molecular signatures associated with OSCC and OPSCC",
    "methodCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://www.nature.com/articles/s41525-021-00257-x",
    "cancerTypes": [
      "Oral squamous cell carcinoma (OSCC)",
      "Oropharyngeal squamous cell carcinoma (OPSCC)"
    ],
    "cancerTypesNotes": "Detects molecular features in saliva associated with oral cavity and throat cancers; similar sensitivity for early and late-stage cancers",
    "targetPopulation": "Adults ≥50 years OR adults ≥18 with tobacco use history (current or past)",
    "indicationGroup": "Oral/Throat Cancer",
    "sensitivity": 90,
    "sensitivityCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://cancerdetect.viome.com/",
    "sensitivityNotes": "90% sensitivity for OSCC; 84.2-90% for OPSCC depending on source. Similar performance across early (Stage I/II) and late (Stage III/IV) stages per validation study.",
    "specificity": 95,
    "specificityCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://cancerdetect.viome.com/",
    "specificityNotes": "94-95% specificity across validation cohorts; 97.9% observed in larger technical validation (n=282)",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://www.nature.com/articles/s41525-021-00257-x",
    "performanceNotes": "Validation cohort of 230 samples (20 OSCC, 76 OPSCC, 134 controls). Earlier Nature study (n=433) showed ROC AUC 0.87 for high-risk population, 0.9+ for OC-only cohort.",
    "fdaStatus": "LDT - FDA Breakthrough Device Designation",
    "fdaStatusNotes": "Lab-developed test performed in CLIA-certified laboratory (Bothell, WA). Received FDA Breakthrough Device designation for accelerated review. Not FDA-approved/cleared.",
    "reimbursement": "Self-pay",
    "reimbursementNote": "Direct-to-consumer test; no insurance coverage. Available via healthcare providers through ViomePRO.",
    "availableRegions": [
      "US"
    ],
    "clinicalAvailability": "Commercially available in US (not available in NY due to state regulations)",
    "tat": "~28 days",
    "tatNotes": "Expect results within 4 weeks per vendor",
    "sampleType": "Saliva rinse (at-home collection)",
    "sampleVolume": "Saliva rinse kit provided",
    "listPrice": 599,
    "listPriceNotes": "$599 list price; promotional pricing available ($299 with DETECT code). Includes healthcare provider consultation if positive result.",
    "numPublications": 2,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/37454545/ | https://www.nature.com/articles/s41525-021-00257-x",
    "numPublicationsNotes": "Banavar et al. Oral Oncology 2023 (validation study, n=1,175); Banavar et al. npj Genomic Medicine 2021 (discovery study, n=433). Both from Viome Research Institute.",
    "totalParticipants": 1175,
    "validationCohortSize": 230,
    "validationCohortStudy": "Prospective validation on 230 samples (20 OSCC, 76 OPSCC, 134 negatives including 14 pre-malignant) from high-risk population ≥50 years or with tobacco history",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA-certified LDT with FDA Breakthrough Device designation; not FDA-approved",
    "vendorVerified": true,
    "vendorRequestedChanges": "2025-01-01: Initial submission by Momchilo Vuyisich (Viome) with peer-reviewed publications. Vendor verified via email momo@viome.com."
  },
  {
    "id": "ecd-26",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "name": "Trucheck Intelli",
    "vendor": "Datar Cancer Genetics",
    "category": "ECD",
    "dateAdded": "Jan 7, 2026",
    "testScope": "Multi-cancer (70+ types)",
    "approach": "Circulating tumor cell (CTC) analysis",
    "method": "Analyzes circulating tumor cells from peripheral blood using epigenetically activated medium for cell stabilization, followed by fluorophore-conjugated antibody characterization against multiple immunocytochemistry markers; quantitative fluorescence imaging on high-content screening platform",
    "methodCitations": "https://uk.datarpgx.com/trucheck-non-invasive-blood-tests | https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22366",
    "cancerTypes": [
      "Adenocarcinoma (21 sites)",
      "Adenosquamous Carcinoma",
      "CNS Malignancies",
      "Gastrointestinal Stromal Tumors",
      "Melanomas",
      "Mesothelioma",
      "Neuroendocrine Tumors",
      "Squamous Cell Carcinoma (20 sites)",
      "Transitional Cell Carcinoma"
    ],
    "cancerTypesNotes": "70+ cancer types across major histological subtypes including AD (bile duct, breast, colon, lung, ovary, pancreas, prostate, etc.), SCC (oral, lung, cervix, skin, etc.), NET, GIST, melanoma, mesothelioma, CNS tumors, and TCC",
    "targetPopulation": "Asymptomatic individuals",
    "indicationGroup": "Multi-Cancer Early Detection",
    "sensitivity": 88.2,
    "sensitivityCitations": "https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22366",
    "sensitivityNotes": "88.24% sensitivity in multi-cancer validation study; based on detection of circulating tumor-associated cell clusters",
    "specificity": 96.3,
    "specificityCitations": "https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22366",
    "specificityNotes": "96.3% specificity in clinical validation",
    "performanceCitations": "https://pubmed.ncbi.nlm.nih.gov/31743438/ | https://pubmed.ncbi.nlm.nih.gov/33029899/ | https://pubmed.ncbi.nlm.nih.gov/32898291/",
    "performanceNotes": "Validated across multiple peer-reviewed publications; hallmark CTC clusters signify 230x higher one-year cancer risk",
    "fdaStatus": "CE-IVD",
    "fdaStatusNotes": "CE-IVD marked in Europe; not FDA-cleared in US",
    "reimbursement": "Self-pay / varies by region",
    "reimbursementNote": "Coverage varies by country; primarily self-pay",
    "availableRegions": [
      "EU",
      "UK",
      "International"
    ],
    "clinicalAvailability": "Commercially available (CE-IVD)",
    "tat": "Up to 14 working days",
    "tatNotes": "14 working days from sample receipt",
    "sampleType": "Venous blood (EDTA)",
    "sampleVolume": "10ml",
    "listPrice": null,
    "listPriceNotes": "Contact vendor for pricing",
    "numPublications": 3,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/31743438/ | https://pubmed.ncbi.nlm.nih.gov/33029899/ | https://pubmed.ncbi.nlm.nih.gov/32898291/",
    "numPublicationsNotes": "Akolkar et al. Int J Cancer 2019 (circulating tumor-associated cell ensembles); Gaya et al. Cancer Cytopathol 2020 (pan-cancer diagnostic triaging); Ranade et al. Cancer Prev Res 2021 (230x one-year cancer risk)",
    "totalParticipants": 40000,
    "totalParticipantsPlus": true,
    "validationCohortSize": 1000,
    "validationCohortStudy": "Multi-center validation across >40,000 participants per vendor; peer-reviewed studies include diagnostic triaging cohort",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "CE-IVD marked; uses CTC approach distinct from ctDNA-based MCED tests",
    "vendorVerified": false,
    "technologyDifferentiator": "CTC-based approach (not ctDNA) - analyzes intact circulating tumor cells rather than fragmented DNA; enables detection of tumor-associated cell clusters which correlate with higher cancer risk; 70+ cancer type coverage using immunocytochemistry markers",
    "submissionInfo": {
      "submittedBy": "Jigar Pandya",
      "submitterEmail": "jigar.pandya@datarpgx.org",
      "submitterType": "expert",
      "submittedDate": "2026-01-07"
    }
  },
  {
    "id": "ecd-27",
    "sampleCategory": "Blood/Plasma",
    "name": "OncoXPLORE+",
    "vendor": "OncoDNA",
    "category": "ECD",
    "dateAdded": "Jan 8, 2026",
    "testScope": "Multi-cancer",
    "approach": "Multi-modal (mutations + CNV + fragmentomics)",
    "method": "Integrates three parallel analytical tracks from a single blood sample: (1) 441-gene targeted panel covering 1.5 Mb including all exonic regions and 20bp flanking regions for SNVs, Indels, fusions, and splicing variants; (2) genome-wide Copy Number Alteration (CNA) profiling via LP-WGS; (3) GIPXplore fragmentomics module using proprietary ML pipeline analyzing genome-wide cfDNA fragmentation signatures for cancer detection and Tissue-of-Origin inference. Built on 15+ years of KU Leuven research.",
    "methodCitations": "https://www.nature.com/articles/s41467-024-46435-0 | https://oncngs.eu | https://oncodna.com",
    "cancerTypes": [
      "Multi-solid tumors",
      "Hematological malignancies"
    ],
    "cancerTypesNotes": "Pan-cancer detection capability; fragmentomics module can infer Tissue-of-Origin for localization. Specific validation data for colorectal cancer, breast cancer, and multiple myeloma.",
    "cancerTypesCitations": "https://www.nature.com/articles/s41467-024-46435-0",
    "targetPopulation": "High-risk asymptomatic individuals, NSAS triage, therapy selection when tissue unavailable",
    "indicationGroup": "Multi-Cancer Early Detection",
    "sensitivity": 53.5,
    "sensitivityCitations": "https://www.nature.com/articles/s41467-024-46435-0 | Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "sensitivityNotes": "~53.5% sensitivity for early-stage cancers at ~99% specificity in asymptomatic screening context. GIPXplore classifier achieved 81.62% overall accuracy with 95% specificity for pan-cancer detection. Cancer-specific AUCs from Nature Comms study: Multiple Myeloma 95.0%, Early-Stage Breast Cancer 90.1%, Colorectal Cancer 84.7%.",
    "specificity": 99,
    "specificityCitations": "https://www.nature.com/articles/s41467-024-46435-0 | Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "specificityNotes": "~99% specificity in early-stage screening context. 95% specificity for pan-cancer GIPXplore classifier. Near 100% specificity for all variant types on targeted panel.",
    "tissueOfOrigin": true,
    "tissueOfOriginAccuracy": 88.7,
    "tissueOfOriginNotes": "88.7% TOO accuracy for true positives using fragmentomics-based cell type deconvolution. Leverages cell-type-specific epigenetic patterns; can identify contributions from 490+ cell types.",
    "tissueOfOriginCitations": "https://www.nature.com/articles/s41467-024-46435-0",
    "lod": "0.3% VAF",
    "lodNotes": "Analytical LoD near 0.3% VAF for targeted 441-gene panel. Technical sensitivity: 88.6% at 0.5% VAF, >93% at 1% VAF, >93% at 2% VAF.",
    "lodCitations": "Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "genesAnalyzed": 441,
    "genesAnalyzedNotes": "441-gene targeted panel covering 1.5 Mb content. Detects SNVs, Indels, fusions, and unusual splicing. Complemented by genome-wide LP-WGS for CNA profiling.",
    "genesAnalyzedCitations": "https://oncodna.com | Vendor data (Christophe Van Huffel, OncoDNA, Jan 2026)",
    "fdaStatus": "RUO (CE-IVDR planned)",
    "fdaStatusNotes": "Currently Research Use Only (RUO) kit for collaborative projects. CE-IVDR technical file submission planned for end of 2026. One of only 2 finalists in EU OncNGS Pre-Commercial Procurement project.",
    "reimbursement": "Not applicable (investigational)",
    "reimbursementNote": "RUO product; no reimbursement pathway currently",
    "availableRegions": [
      "EU (RUO)"
    ],
    "clinicalAvailability": "RUO kit for collaborative projects; Phase 3 OncNGS clinical validation ongoing through March 2026",
    "clinicalTrials": "OncNGS Phase 3 clinical validation at 7 European pilot hospitals including Institut Curie (France), Ludwig Maximilians University (Germany), Institut Jules Bordet (Belgium)",
    "clinicalTrialsCitations": "https://oncngs.eu/index.php/phase3/",
    "totalParticipants": null,
    "validationCohortSize": 744,
    "validationCohortStudy": "Nature Communications 2024 study: 744 healthy individuals and patients (Stanley et al.)",
    "numPublications": 2,
    "numPublicationsPlus": true,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/38472221/ | https://academic.oup.com/bioinformatics/article/40/9/btae522/7739698",
    "numPublicationsNotes": "Stanley/Vermeesch et al., Nature Communications 2024 (cell type signatures in cfDNA fragmentation); Passemiers/Vermeesch et al., Bioinformatics 2024 (MetDecode methylation-based deconvolution). Additional OncNGS consortium publications in progress.",
    "isRUO": true,
    "isInvestigational": true,
    "isClinicalLDT": false,
    "regulatoryStatusNotes": "RUO product in OncNGS Phase 3 clinical validation (through March 2026). CE-IVDR submission planned end of 2026. Integrated into OncoKDM platform (registered medical device, GDPR compliant).",
    "technologyDifferentiator": "Multi-modal liquid biopsy combining mutations + CNV + fragmentomics in single workflow. GIPXplore fragmentomics leverages cell-type-specific epigenetic patterns to detect cancer signals even when specific mutations are unknown or at very low concentrations. Tumor-naïve approach - no prior tissue biopsy required. Built on 15+ years of KU Leuven research. One of only 2 finalists in EU OncNGS Pre-Commercial Procurement.",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Initial submission by Christophe Van Huffel (OncoDNA) with detailed vendor responses to clarification questions. Performance data from Nature Communications 2024 and internal validation cohorts.",
    "submissionInfo": {
      "submittedBy": "Christophe Van Huffel",
      "submitterEmail": "c.vanhuffel@oncodna.com",
      "submitterType": "vendor",
      "submittedDate": "2025-12-09",
      "clarificationDate": "2026-01-08"
    }
  },
  {
    "id": "ecd-23",
    "sampleCategory": "Blood/Plasma",
    "sampleVolumeMl": 10,
    "sampleCitations": "https://www.earlydx.com/",
    "name": "MethylScan HCC",
    "vendor": "EarlyDx",
    "productType": "Central Lab Service",
    "website": "https://www.earlydx.com/",
    "approach": "Tumor-naïve",
    "method": "DNA methylation biomarkers via targeted multiplexed NGS; 5 CpG sites (HCC-detect: CHFR, VASH2, CCNJ, GRID2IP + HCC-spec: F12)",
    "methodCitations": "https://doi.org/10.1038/s41467-023-39055-7",
    "methodNotes": "Bisulfite conversion followed by targeted NGS. HCC-detect panel (4 CpGs) identifies hepatocyte-derived cfDNA; HCC-spec marker (F12 gene) distinguishes HCC from benign liver disease. Combined test branded as 'epiLiver' in validation study.",
    "cancerTypes": [
      "Hepatocellular carcinoma (HCC)"
    ],
    "targetPopulation": "Adults at high risk for HCC including those with cirrhosis, chronic hepatitis B/C, or other liver disease",
    "indicationGroup": "Liver",
    "sensitivity": 84.5,
    "sensitivityCitations": "https://doi.org/10.1038/s41467-023-39055-7",
    "sensitivityNotes": "84.5% sensitivity at 95% specificity threshold (n=554 clinical validation in Dhaka). AUC 0.94. Performance maintained across all BCLC stages. Superior to AFP alone (85% vs 61% sensitivity).",
    "stageISensitivity": 73,
    "stageISensitivityCitations": "https://doi.org/10.1038/s41467-023-39055-7",
    "stageISensitivityNotes": "73% sensitivity for BCLC Stage A (early-stage) HCC. Some sources cite 75%. Stage-independent detection due to categorical (not quantitative) methylation differences.",
    "specificity": 92,
    "specificityCitations": "https://doi.org/10.1038/s41467-023-39055-7",
    "specificityNotes": "92% specificity in clinical validation. Study also reported 95% specificity at different threshold. High specificity for HCC vs other cancer types (tested against 31 cancer types in TCGA, n=8,754).",
    "ppv": null,
    "ppvCitations": "",
    "ppvNotes": "PPV not reported in primary validation study",
    "npv": null,
    "npvCitations": "",
    "npvNotes": "NPV not reported in primary validation study",
    "testScope": "Single-cancer (HCC)",
    "tat": 10,
    "tatNotes": "Estimated turnaround time",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Available as laboratory-developed test through CLIA/CAP accredited laboratory",
    "reimbursement": "Has PLA code and CMS pricing determination; working with MolDx for LCD reimbursement",
    "reimbursementNote": "Coverage emerging through Medicare LCD pathway",
    "clinicalAvailability": "Available via test requisition form or physician portal",
    "availableRegions": [
      "US"
    ],
    "listPrice": null,
    "listPriceNotes": "Contact vendor for pricing",
    "clinicalTrials": "Clinical validation study (n=554) in Dhaka, Bangladesh",
    "clinicalTrialsCitations": "https://doi.org/10.1038/s41467-023-39055-7",
    "totalParticipants": 554,
    "numPublications": 1,
    "numPublicationsCitations": "https://doi.org/10.1038/s41467-023-39055-7",
    "numPublicationsNotes": "Zhang et al. Nature Communications 2023 - 'A high-throughput test enables specific detection of hepatocellular carcinoma'",
    "validationCohortSize": 554,
    "validationCohortStudy": "Prospective clinical validation in high-HCC-burden population (Dhaka, Bangladesh): 302 HCC patients (BCLC A=34, B=86, C=106, D=76), 46 controls, 49 CHB, 102 non-HCC cancers, 50 healthy plasma",
    "isRUO": false,
    "isInvestigational": false,
    "isClinicalLDT": true,
    "regulatoryStatusNotes": "CLIA LDT with PLA code. Available for clinical ordering.",
    "technologyDifferentiator": "Methylation-based approach detects HCC-specific epigenetic changes rather than mutations. Markers are categorically methylated in HCC (binary signal) vs unmethylated in normal tissue, providing robust detection even at low tumor burden. Unique specificity for HCC vs other liver conditions and other cancer types.",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-12: Initial submission by Lara Baden (EarlyDx) with performance data from Nature Communications 2023. Commercial availability confirmed with PLA code.",
    "submissionInfo": {
      "submittedBy": "Lara Baden",
      "submitterEmail": "lara.baden@earlydx.com",
      "submitterType": "vendor",
      "submittedDate": "2026-01-12"
    }
  }
]